

**Contribution of *BRCA1/2*
Mutation Testing to Risk
Assessment for Susceptibility to
Breast and Ovarian Cancer**

Summary Report

AGENCE D'ÉVALUATION DES TECHNOLOGIES
ET DES MODES D'INTERVENTION EN SANTÉ

Contribution of *BRCA1/2* Mutation Testing to Risk Assessment for Susceptibility to Breast and Ovarian Cancer

Summary Report

Report prepared for AETMIS by Julie Tranchemontagne,
Lucy Boothroyd and Ingeborg Blancquaert

March 2006

The content of this report was written and produced by the Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS). Both the original summary report and its French version, titled *Contribution des analyses moléculaires des gènes BRCA1/2 à l'évaluation du risque de prédisposition au cancer du sein ou de l'ovaire : rapport sommaire*, are available in PDF format on the Agency's Web site.

Scientific review

Dr. Ingeborg Blancquaert

Proofreading

Jocelyne Lauzière, C. Tr.

Page layout

Jocelyne Guillot

Bibliographic research

Denis Santerre

Coordination

Lise-Ann Davignon

For further information about this publication or any other AETMIS activity, please contact:

Agence d'évaluation des technologies et des modes d'intervention en santé
2021, Union Avenue, suite 1050
Montréal (Québec) H3A 2S9

Telephone: (514) 873-2563
Fax: 514-873-1369
E.mail: aetmis@aetmis.gouv.qc.ca
www.aetmis.gouv.qc.ca

How to cite this document:

Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS). Contribution of *BRCA1/2* Mutation Testing to Risk Assessment for Susceptibility to Breast and Ovarian Cancer: Summary Report. Report prepared by Julie Tranchemontagne, Lucy Boothroyd and Ingeborg Blancquaert (AETMIS 06-02). Montréal: AETMIS, 2006, vii–38 p.

Legal deposit

Bibliothèque nationale du Québec, 2006

Library and Archives Canada, 2006

ISBN 2-550-46358-7 (Print) (French edition ISBN 2-550-46356-0)

ISBN 2-550-46359-5 (PDF) (French edition ISBN 2-550-46357-9)

© Gouvernement du Québec, 2006.

This report may be reproduced in whole or in part provided that the source is cited.

MISSION

The mission of the Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) is to contribute to improving the Québec health-care system and to participate in the implementation of the Québec government's scientific policy. To accomplish this, the Agency advises and supports the Minister of Health and Social Services as well as the decision-makers in the health-care system, in matters concerning the assessment of health services and technologies. The Agency makes recommendations based on scientific reports assessing the introduction, diffusion and use of health technologies, including technical aids for disabled persons, as well as the modes of providing and organizing services. The assessments take into account many factors, such as efficacy, safety and efficiency, as well as ethical, social, organizational and economic implications.

EXECUTIVE

Dr. Luc Deschênes

Cancer Surgeon, President and Chief Executive Officer of AETMIS, Montréal, and Chairman, Conseil médical du Québec, Québec

Dr. Véronique Déry

Public Health Physician, Chief Executive Officer and Scientific Director

Dr. Reiner Banken

Physician, Deputy Chief Executive Officer, Development and Partnerships

Dr. Alicia Framarin

Physician, Deputy Scientific Director

Jean-Marie R. Lance

Economist, Senior Scientific Advisor

BOARD OF DIRECTORS

Dr. Jeffrey Barkun

Associate Professor, Department of Surgery, Faculty of Medicine, McGill University, and Surgeon, Royal Victoria Hospital (MUHC), Montréal

Dr. Marie-Dominique Beaulieu

Family Physician, Holder of the Dr. Sadok Besrouer Chair in Family Medicine, CHUM, and Researcher, Unité de recherche évaluative, Hôpital Notre-Dame (CHUM), Montréal

Dr. Suzanne Claveau

Specialist in microbiology and infectious diseases, Hôtel-Dieu de Québec (CHUQ), Québec

Roger Jacob

Biomedical Engineer, Coordinator, Capital Assets and Medical Equipment, Agence de la santé et des services sociaux de Montréal, Montréal

Denise Leclerc

Pharmacist, Board Member of the Institut universitaire de gériatrie de Montréal, Montréal

Louise Montreuil

Assistant Executive Director, Direction générale de la coordination ministérielle des relations avec le réseau, ministère de la Santé et des Services sociaux, Québec

Dr. Jean-Marie Moutquin

Obstetrician/Gynecologist, Research Director, and Executive Director, Département d'obstétrique-gynécologie, CHUS, Sherbrooke

Dr. Réginald Nadeau

Cardiologist, Hôpital du Sacré-Cœur, Montréal, Board Member of the Conseil du médicament du Québec

Guy Rocher

Sociologist, Professor, Département de sociologie, and Researcher, Centre de recherche en droit public, Université de Montréal, Montréal

Lee Soderström

Economist, Professor, Department of Economics, McGill University, Montréal

NOTE TO READER

This report is a summary of a monograph intended as a first step in a broader analysis of the use of tests for detecting *BRCA1/2* gene mutations and the issues relating thereto. The monograph, like this summary report that stems from it, describes the nature of the evidence concerning the use of this genetic technology and discusses the unresolved questions and uncertainties that complicate the decision-making process. AETMIS is also preparing a complementary report, which examines, among other things, the organizational and economic aspects. This second report will make it possible to draw conclusions regarding the decision-making issues raised by the use of molecular testing.



FOREWORD

CONTRIBUTION OF *BRCA1/2* MUTATION TESTING TO RISK ASSESSMENT FOR SUSCEPTIBILITY TO BREAST AND OVARIAN CANCER

SUMMARY REPORT

This health technology assessment was undertaken following a request from the Québec Ministry of Health and Social Services (MSSS, Ministère de la Santé et des Services sociaux). Questions had been brought to the attention of the MSSS by the Québec health insurance agency (RAMQ, Régie de l'assurance maladie du Québec) regarding whether sending samples to a private laboratory for the sequencing of *BRCA1* and *BRCA2* genes was justified, and which indications for testing should be followed. Additional concerns were raised by the Québec Association of Medical Geneticists (AMGQ, Association des médecins généticiens du Québec) regarding the organization of cancer genetics services in the province. The MSSS request asked AETMIS to consider a broad range of issues, including 1) *BRCA1/2* molecular test validity; 2) testing indications; 3) psychosocial and ethical implications; 4) impact on clinical management; 5) cost-effectiveness; and 6) organizational aspects of cancer genetics service delivery.

Since the Canadian Coordinating Office of Health Technology Assessment (CCOHTA) had also received a mandate to review *BRCA1/2* testing, a collaboration between CCOHTA and AETMIS was established to avoid duplication of work. The present document summarizes a monograph which is the result of the analysis undertaken at AETMIS on 1) prevalence and penetrance of *BRCA1/2* mutations; 2) risk assessment models and testing indications; 3) clinical validity of molecular tests; and 4) the impact of molecular testing on risk assessment and genetic counselling. The forthcoming CCOHTA report will address the analytical validity of molecular tests, the potential benefits of molecular testing for clinical management, and the psychosocial and ethical issues. The complementary nature of the work undertaken by the AETMIS and CCOHTA researchers is clearly an asset, but overall conclusions in this area will need to take the content of both reports into account. The scope of the present work does not therefore allow recommendations to be made regarding the complex range of questions related to the clinical use of *BRCA1* and *BRCA2* molecular tests.

A follow-up AETMIS report is also in preparation, which will build upon the present work, the CCOHTA report, and other systematic reviews on selected topics, as well as the research undertaken at AETMIS with respect to organizational and economic issues related to cancer genetics services. This broader-ranging review will allow conclusions to be drawn with regard to the policy questions raised by the use of genetic testing technology. The current summary report provides an understanding of the nature of the scientific evidence that needs to underpin these decisions and of the unresolved questions and uncertainties that complicate the decision-making process.

The purpose of health technology assessment is to examine the use of a specific technology for a given target condition and population. For diagnostic tests, the central question is that of the contribution of the technology to the diagnosis and management of the target condition (be it a disease or a risk factor for disease). Defining the target condition is somewhat problematic in the case of the present assessment. Current clinical practice does not support the widespread use of *BRCA1* and *BRCA2* molecular testing for all cases of breast cancer and their families. Instead, families with

a high prior probability of carrying a genetic susceptibility to breast and ovarian cancer, on the basis of family history and ethnic origin, are targeted. With a view to coherence with the above perspective and given that clinical management was not covered in this review, the present report focuses on the contribution of *BRCA1* and *BRCA2* testing to risk assessment for susceptibility to breast and ovarian cancer.

Dr. Luc Deschênes

President and Chief Executive Officer

ACKNOWLEDGEMENTS

This report was prepared at the request of the Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) by Julie Tranchemontagne, MSc (Biochemistry, Genetic Counselling), Lucy Boothroyd, MSc (Epidemiology and Biostatistics), PhD Candidate, and Dr. Ingeborg Blancquaert, MD (Pediatrics), PhD (Epidemiology), all three AETMIS Consultant Researchers.

AETMIS would like to express its appreciation to the members of the Genetics Advisory Committee, who took the time to read and comment on the monograph on which this summary report is based:

Guy Bourgeault

Professor, Département d'administration et fondements de l'éducation, Faculty of Education, Université de Montréal, Québec

Dr. William Foulkes

Medical Geneticist, Researcher, Research Institute of the McGill University Health Centre (MUHC), and Director, Cancer Genetics Program, Department of Oncology, Faculty of Medicine, McGill University, Montréal, Québec

Dr. Rachel Laframboise

Medical Geneticist, Head of the Medical Genetics Department, Centre mère-enfant of the Centre hospitalier de l'Université Laval (CHUL-CME), Centre hospitalier universitaire de Québec (CHUQ), and Associate Professor, Department of Pediatrics, Université Laval, Québec

Dr. Grant A. Mitchell

Medical Geneticist, Researcher, Research Centre of the CHU Sainte-Justine, and Professor, Department of Pediatrics, Faculty of Medicine, Université de Montréal, QuébecDr. -

Dr. Suzanne Philips-Nootens

Professor, Assistant Dean, Research and Graduate Studies, and Director, Programs in Law and Health Policies, Faculty of Law, Université de Sherbrooke, Québec

Dr. Marie-France Raynault

Director, Department of Social and Preventive Medicine, Faculty of Medicine, Université de Montréal, Québec

Dr. David S. Rosenblatt

Medical Geneticist, Chair, Department of Human Genetics, Faculty of Medicine, McGill University, Montréal, Québec

Dr. François Rousseau

Physician and Biochemist, Hôpital Saint-François d'Assise, Centre hospitalier universitaire de Québec (CHUQ), Researcher, Human and Molecular Genetics Unit, CHUQ, and Professor, Department of Medical Biology, Faculty of Medicine, Université Laval, Québec

The Agency also wishes to thank the external reviewers for their valuable comments and their contribution to the quality and accuracy of the present document:

Dr. Pierre Chappuis

Associate Physician, Department of Oncology, Department of Medical Genetics, Hôpitaux universitaires de Genève, Suisse

Prof. Gareth Evans

Professor in Medical Genetics, Regional Genetic Service, St.Mary's Hospital for Women and Children, United Kingdom

Prof. John Hopper

Director, Centre for Genetic Epidemiology and Australian Twin Registry, University of Melbourne, Australia

Dr. Doug Horseman

Director, Cancer Genetics Laboratory and Hereditary Cancer Program, BC Cancer Agency, British Columbia

Dr. Glenn E. Palomaki

Assistant Director, Division of Medical Screening, Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Providence, Rhode Island, United States

Prof. Jacques Simard

Canada Research Chair in Oncogenetics, Department of Anatomy and Physiology, Faculty of Medicine, Université Laval, Director, Laboratory of Cancer Genomics, Research Centre of the Centre hospitalier de l'Université Laval (CHUL), Centre hospitalier universitaire de Québec (CHUQ), Québec, and Director, INHERIT BRCA

The Agency would like to express its gratitude to the clinicians and researchers whose comments have greatly enriched this document:

Dr. **William Foulkes** and Dr. **Doug Horseman** met with the authors and provided them with information on risk assessment and *BRCA1/2* testing indications; **Cathy Gilpin**, Children's Hospital of Eastern Ontario and **Karen Panabaker**, BC Cancer Agency, both Genetic Counsellors, provided information on statistical models for risk assessment in oncogenetics clinics; Dr. **Jacques Simard** shared results of his research on *BRCA1/2* mutations in the French Canadian population.

AETMIS wishes to thank the members and collaborators of the Canadian Coordinating Office for Health Technology Assessment (CCOHTA) who contributed to the preparation and review of this report:

Dr. Judith Allanson, Clinical Expert, and **Sherry Taylor**, Molecular Expert, helped develop the assessment protocol, provided advice on identifying the scientific literature, and reviewed a preliminary version of the monograph.

Diane Benner and **Pat Reynard**, Project Managers, assisted in the administrative coordination of the project.

Dr. Ruth Collins-Nakai and **Dr. Ken Marshall**, members of CCOHTA's Scientific Board, reviewed the assessment protocol and a preliminary version of the monograph.

Chuong Ho, **Ritsuko Kakuma**, **Ken Bassett** and **Hussein Noorani**, Researchers, contributed to the assessment protocol and provided comments on a preliminary version of the monograph.

Janet Joyce, Director, Library and Information Services, prepared the literature search strategy in collaboration with the researchers, and performed the search until June 2004.

Linda McGahan, Researcher, contributed to the assessment protocol and a preliminary version of the monograph.

Eugenia Palylyk-Colwell, Consultant Editor, reviewed a preliminary version of the monograph.

Lastly, the Agency wishes to thank the members of its research and support staff for their contribution:

Dr. Alicia Framarin, Deputy Scientific Director, **Maria-Edith Jacques**, Secretary, **Laura Robb**, Consultant Researcher, **Alexandra Obadia**, Lawyer, Consultant Researcher, **Dr. Stéphane Perron**, Consultant Researcher, and **Lise Turcotte**, Executive Secretary.

DISCLOSURE OF CONFLICT OF INTEREST

None declared.

TABLE OF CONTENTS

MISSION	i
NOTE TO READER.....	ii
FOREWORD	iii
ACKNOWLEDGEMENTS.....	v
1 INTRODUCTION.....	1
2 METHODS.....	3
3 MUTATION PREVALENCE.....	4
4 PENETRANCE.....	6
5 RISK ASSESSMENT	8
6 GUIDELINES FOR TESTING INDICATIONS	9
7 CLINICAL VALIDITY	10
8 IMPACT OF TESTING ON RISK ASSESSMENT AND GENETIC COUNSELLING.....	12
9 CONCLUSION	14
APPENDIX A	15
REFERENCES	17

LIST OF TABLES

Table 1	<i>BRCA1/2</i> mutation prevalence in different populations.....	4
Table 2	Penetrance of <i>BRCA1/2</i> mutations for breast cancer estimated in different populations	6
Table 3	Penetrance of <i>BRCA1/2</i> mutations for ovarian cancer estimated in different populations	7

For both breast and ovarian cancer the strongest known risk factor, after adjusting for age, is family history. The figure most often cited is that approximately 1/3 of breast cancer is *familial*, where family history is defined by the presence of at least two cases of breast cancer, at any age, in first- or second-degree relatives. Approximately 5% of all breast cancer cases are currently thought to be hereditary, that is, related to the transmission of mutations in a single gene. Clustering of cancer cases in families does not imply that genetic susceptibility is always present, since environmental factors and chance can also play a role. Conversely, the presence of a genetic susceptibility will not always translate into the occurrence of multiple cancer cases within one family. However, persons considered to be at highest risk of carrying a mutation in a breast or ovarian cancer susceptibility gene are those displaying the characteristics of a hereditary breast and ovarian cancer syndrome, HBOC. The HBOC syndrome is characterized by a pattern of occurrence of cancers in a family, involving multiple relatives affected by breast and/or ovarian cancer, and by early age at diagnosis. Currently, there is no consensus as to the minimal set of criteria defining an HBOC family.

Two genes conferring susceptibility to breast and ovarian cancer have been associated with HBOC: Breast Cancer gene 1 (*BRCA1*) on chromosome 17 and Breast Cancer gene 2 (*BRCA2*) on chromosome 13. The mutations¹ in the *BRCA1* or *BRCA2* genes are transmitted via an autosomal dominant mode of inheritance.² Since the cloning of *BRCA1* and *BRCA2*, in 1994 and 1995 respectively, more than a thousand mutations have been identified in these very large genes.³ Many of the *BRCA1/2* mutations occur in only one or a few families, except in certain ethnic groups where a

founder effect⁴ appears to exist. Slight homology exists between the *BRCA1* and *BRCA2* proteins, and both have a function in DNA repair. *BRCA1/2* genes are considered to be tumour suppressor genes. In general, tumour development related to this class of genes occurs when two copies of mutated alleles⁵ are present. This implies that carrying an inherited mutated allele is not a sufficient condition for abnormal cell growth and that inactivation of the second, normal allele is a necessary step for carcinogenesis.

According to population-based studies, *BRCA1/2* mutations explain 16–17% of the clustering of breast cancer in families,⁶ compared to 55–60% of the clustering in ovarian cancer. However, the contribution of *BRCA1/2* to familial breast or ovarian cancer may be greater in certain ethnic groups with a founder effect, such as Ashkenazi Jewish or Icelandic. At the moment, a substantial proportion of familial breast cancer cases has not been linked to any known breast or ovarian cancer susceptibility gene, and clustering of cancer cases in these families is most likely related to low penetrance⁷ genes, environmental factors or a combination of both. The isolation of genetic variants associated with a lower risk of developing cancer poses an important challenge, even though their prevalence could be substantially greater than that of high penetrance genes such as *BRCA1/2*. Indeed, they rarely produce a familial pattern that is striking enough for the traditional analysis used to localize genes.

Since the cloning of *BRCA1/2*, considerable progress has been made in the understanding of the role of the *BRCA1/2* mutations in carcinogenesis, in their characterization in a variety of populations,

1. A mutation is an alteration occurring in the deoxyribonucleic acid or DNA sequence that can result in pathological manifestations.

2. This mode of inheritance implies that mutations on chromosomes other than sex chromosomes have a 50% risk of being transmitted to a carrier's offspring.

3. Each gene spans more than 100 kb of DNA.

4. A founder effect refers to the occurrence of a higher frequency of one or more specific mutations in descendants of a group of common ancestors (founder population), as a result of geographic and/or ethnic isolation.

5. Alleles are alternate forms of a given gene that differ in their nucleotide sequence.

6. Familial cancer is defined here as at least two family members being affected by cancer among first-degree relatives (parent, sibling or child).

7. Penetrance refers to the proportion of individuals with a given genetic variant in whom the manifestations related to that genetic variant are expressed. Penetrance of *BRCA1/2* mutations is measured by the cumulative risk of cancer at a given age.

and in the assessment of the risk of developing cancer for *BRCA1/2* mutation carriers. Molecular tests to detect mutations have been developed, but the transition from research to clinical practice has occurred under a variety of conditions and at a different pace from one centre to the next. Even today, substantial heterogeneity can be observed in terms of the precise testing indications, the analytical techniques used, the organization of services accompanying testing, and the professionals involved in these services. This heterogeneity, in turn, means that combining and making sense of the evidence in this complex field is particularly challenging.

In order to reflect both current clinical practice and the emphasis in the scientific literature, our analysis of the contribution of *BRCA1/2* testing to risk assessment focuses on individuals with a high prior probability (that is, at high risk) of carrying a genetic susceptibility to breast and ovarian cancer. This includes families thought to fit the definition(s) of a hereditary cancer syndrome, as well as individuals with other risk-related characteristics, such as early age at onset of cancer.

The present summary report summarizes a monograph⁸ that is part of a broader project. As a first step, a systematic literature review was conducted with respect to:

- 1) the prevalence of *BRCA1/2* mutations in HBOC families, breast or ovarian cancer cases, and certain founder populations,
- 2) the penetrance associated with *BRCA1/2* mutations,
- 3) the available risk assessment models,

- 4) existing guidelines as to testing indications, and
- 5) the clinical validity of available molecular tests.

The evidence retrieved from the systematic review was integrated to provide an understanding of the contribution of molecular tests to risk assessment and genetic counselling of individuals and families with HBOC, understood in a broad sense, and to situate these findings within the wider context of decision and policy-making issues related to the clinical use of *BRCA1/2* mutation testing. A complete reference list is presented at the end of this summary report; citation of data sources can be found in the full monograph.

Important considerations, such as the analytical validity or technical performance of available tests, the psychosocial consequences of testing, the impact of testing on clinical management, and the ethical and legal issues raised by the use of these tests in clinical practice, either have been dealt with in recent systematic reviews or are the object of ongoing projects elsewhere.⁹ Such topics will not be covered here, but the conclusions of these reviews will be taken into account in a follow-up document to the present report,¹⁰ which will cover issues of particular concern to policy makers. This companion report will include a review of organizational modalities of cancer genetics services in different jurisdictions, a review of the impact of models of care delivery on psychosocial consequences of testing, and a comparative cost analysis for different organizational modalities.

8. Tranchemontagne J, Boothroyd L, Blancquaert I. Contribution of *BRCA1/2* Mutation Testing to Risk Assessment for Susceptibility to Breast and Ovarian Cancer. Montréal: AETMIS, 2006.

9. Foundation for Blood Research (FBR). Family history and *BRCA1/2* testing for identifying women at risk for inherited breast/ovarian cancer (preliminary report) (www.cdc.gov/genomics/gtesting/ACCE/FBR.htm); CCOHTA (Canadian Coordinating Office for Health Technology Assessment). Systematic review of *BRCA1* and *BRCA2* genetic testing for breast and ovarian cancer susceptibility (in preparation); US Preventive Services Task Force/Agency for Healthcare Research and Quality (USPSTF/AHRQ). Genetic risk assessment and *BRCA* mutation testing for breast and ovarian cancer susceptibility. Evidence Synthesis No. 37, 2005 (www.ahrq.gov/clinic/uspstf/uspbrgen.htm).

10. AETMIS. Cancer Genetic Services: Economic and Organizational Issues (in preparation).

A comprehensive search strategy using key words was designed in order to identify published, 'grey', and unpublished literature for each topic. The search was limited to human studies, and there were no language restrictions. A draft set of key words was tested for its precision before finalization. Databases of published literature were searched through December 2004. The reference lists of primary research studies, review articles, and reports were searched to identify other relevant articles. The detailed literature search strategies and study selection criteria used for the assessment are presented in Appendix A.

Two reviewers independently made the final selection of studies to be included in the review based on the selection criteria. Study selection

forms were developed and pilot tested for this purpose. The decision to order an article was based on the title and abstract, where available. In cases where these offered insufficient information, the article was ordered for further information. The degree of agreement between reviewers was noted, and any persisting differences were resolved by consensus. For articles containing quantitative data, forms that were specifically developed and pilot tested for this project were used to extract data. Various procedures were put in place to ensure quality control, including checking of extracted data by a second reviewer, discussion of all particularly complex articles by several reviewers, and reading of text and tables by a scientific reviewer not directly involved in data extraction.

The prevalence of mutations varies according to the geographic and ethnic origin(s) of the population. Prevalence estimates also vary substantially according to study sample selection criteria, in particular with respect to family history and age at diagnosis. Therefore, *BRCA1/2* mutation prevalence data are reviewed separately for 1) individuals with a family history of breast or ovarian cancer; 2) individuals with these cancers that were not selected on the basis of family history; 3) the general population; and 4) several founder populations.

Table 1 provides an overview of the ranges of values observed depending on the type of population under study. Where several studies were reviewed for a given category, only the extreme values are reported, that is, the results of the studies yielding the lowest and highest

point estimates of mutation prevalence. Data were not combined across studies because of the heterogeneity of results and variability in inclusion criteria, mutation detection techniques, and mutation frequency distributions. Confidence intervals for single studies are presented when available. A number of trends can be observed but formal statistical comparisons across study results were not performed. Estimated frequency of *BRCA1/2* mutations in families ascertained because of multiple cases of cancer is, in general, higher than in individuals referred to cancer clinics due to family history, at least on the basis of point estimates for proportion of linked families or mutation prevalence, respectively. In cancer cases unselected for family history, prevalence point estimates tend to be lower for breast than for ovarian cancer cases, unless breast cancer cases are selected on the basis of early age at onset.

TABLE 1

***BRCA1/2* mutation prevalence in different populations**

TYPE OF POPULATION		FREQUENCY OF <i>BRCA1/2</i> MUTATIONS, % (95% CI, IF AVAILABLE)			
		<i>BRCA1</i>		<i>BRCA2</i>	
		MINIMUM VALUE*	MAXIMUM VALUE*	MINIMUM VALUE*	MAXIMUM VALUE*
Families ascertained for gene identification (multiple cases of cancer)		52† (42–62)		32† (22–43)	
Individuals referred to cancer clinics due to family history		3.5	45.0	1.2	22.5
Breast cancer cases§	Unselected for age at diagnosis	1.1 (0.4–2.2)	2.6 (0–5.5)	1.1‡ (0.4–2.2)	
	Selected for early age at diagnosis	0.7 (0.3–1.3)	6.0 (3.8–8.8)	1.3 (0.8–2.1)	3.9 (2.2–6.3)
Ovarian cancer cases (unselected for age at diagnosis and family history)		1.9	9.6 (6.7–13.5)	0.9	4.1

* Where several studies were reviewed for a given category, only the results of the studies yielding the lowest and highest point estimates of mutation prevalence are presented.

† These figures are proportions of linked families and incorporate partial *BRCA1* mutation analysis.

‡ Only one study was identified by our search methodology.

§ All but one study include cases unselected for family history of breast/ovarian cancer and are from heterogeneous populations.

Up to 36% of women with breast cancer who are mutation carriers report no family history of breast or ovarian cancer. In the Ashkenazi Jewish population, between 1.9 and 2.7% of individuals are estimated to be carriers of one of three common mutations, which is approximately ten times the overall carrier prevalence estimated in heterogeneous¹¹ populations. *BRCA1/2* mutation frequencies in heterogeneous general populations have been extrapolated from breast cancer series.

Stratified analyses show that mutation prevalence is associated with various risk factors: breast cancer diagnosed at an early age, specific ethnic origin (e.g., Ashkenazi Jewish), ovarian cancer and male breast cancer. Cut-off values for defining 'early' age at diagnosis of breast cancer vary widely in the literature, and there is no general agreement as to the value that justifies offering tests on the basis of age as the only risk factor. The discriminating power of the number of breast cancer cases and the presence of bilateral cancer as risk factors appear to depend on the presence of ovarian cancer in the family history and age of onset of cancer, respectively.

The fact that recurrent mutations have been discovered in certain populations makes the molecular analysis of the *BRCA1/2* genes easier for these groups, since one can screen for common mutations first rather than proceeding directly to screen all exons.¹² However, the testing strategy should take the importance of the founder effect into account. The three most striking examples of founder mutations are those in the Ashkenazi Jewish (AJ), Icelandic and Polish populations. When testing is performed, it is common to screen for selected founder mutations in some ethnic groups (e.g., AJ), while optimal approaches have not yet been established in other founder populations, such as French Canadians.¹³

Currently, the molecular testing of *BRCA1/2* genes yields a fairly large proportion of variants of unknown clinical significance. This raises the problem of classifying and interpreting these test results, deciding whether or not to include them in prevalence calculations, and choosing appropriate clinical follow-up strategies.

11. Heterogeneous refers to the diverse ethnic and geographic origins of the population.

12. Exons are gene sequences whose transcripts persist in the final messenger RNA and which can therefore be translated into a polypeptide chain.

13. A variety of reasons explain this situation, including a higher number of common mutations, a limited number of studies, and possibly, geographic variation of mutation distribution in the province of Québec.

For *BRCA1/2* mutation carriers, penetrance is defined as the cumulative risk of developing cancer, either up to a specific age or during lifetime. The penetrance of the *BRCA1/2* genes is less than 100% and is therefore said to be incomplete. *BRCA1/2* mutations are nevertheless associated with a high risk of breast and ovarian cancer, clearly elevated over that of the general population. Absolute risks of cancers other than breast or ovarian, such as prostate or male breast cancers, appear to be relatively small.

Tables 2 and 3 provide, for breast and ovarian cancer respectively, an overview of the ranges of penetrance values observed for multiple-case families, clinic-based families, and cancer cases unselected for family history. As in Table 1, data were not combined across studies and only extreme estimates are presented. In studies on families with more than four affected individuals, estimated risk of breast cancer at age 70 is similar for *BRCA1* mutations and *BRCA2* mutations, but risk of ovarian cancer appears to be higher for *BRCA1* than for *BRCA2*. The only published meta-analysis, in which data from 22 studies on heterogeneous and founder populations unselected for family history were pooled, yields lower point estimates for risk of breast cancer at age 70 than studies of highly selected families (i.e., 65% for *BRCA1* mutations and 45% for *BRCA2* mutations). In this meta-analysis, ovarian cancer risk was statistically significantly higher for mutations in *BRCA1* (39%) than in *BRCA2* (11%). Breast cancer risk point estimates for individuals referred to specialized clinics due to family history seem to fall in between the values reported above.

The risk of developing breast and ovarian cancer for carriers of the three founder mutations in

the Ashkenazi Jewish (AJ) population has been extensively studied and some studies provide mutation-specific estimates. In contrast, penetrance of *BRCA1/2* mutations has only been estimated in one study of French Canadian high-risk families. Results are in line with estimates of penetrance among high-risk families from other ethnic groups, but confidence intervals are particularly large.

Penetrance estimates with respect to breast and ovarian cancer vary widely from study to study. In general, confidence intervals are wide, rendering most differences between point estimates statistically non-significant. Analyses are under way to examine whether the observed differences are attributable to the effects of disparate designs and analytical methodologies, or to real differences between high-risk and moderate-risk populations. With the exception of certain populations, where penetrance has been determined for specific founder *BRCA1/2* mutations (e.g., AJ, Icelandic, Norwegian), estimates to date are mean values for a broad range of *BRCA1/2* mutations. Given the number of different factors that influence the phenotypic expression of hereditary breast cancer,¹⁴ a more precise personal cancer risk assessment is likely to be unrealistic, especially in heterogeneous populations. Contradictions exist between studies on cancer risk modifiers and these cannot be used presently at the clinical level. At the moment, the information on penetrance is conveyed to patients and families as a range of values derived from empirical data on groups of families with similar risk factors. No biological markers are currently available to predict which *BRCA1/2* mutation carriers will develop cancer. In practice, family pedigree information and ethnicity are used to modulate risk assessment.

14. Factors modulating cancer risk include the type of *BRCA1/2* mutation as well as risk modifiers such as reproductive, environmental and other genetic factors.

TABLE 2

Penetrance of *BRCA1/2* mutations for breast cancer estimated in different populations

TYPE OF POPULATION	PENETRANCE OF <i>BRCA1/2</i> MUTATIONS AT 70 YEARS, % (95% CI, IF AVAILABLE)			
	<i>BRCA1</i>		<i>BRCA2</i>	
	MINIMUM VALUE*	MAXIMUM VALUE*	MINIMUM VALUE*	MAXIMUM VALUE*
Families ascertained for gene identification (multiple cases of cancer [†])	85	87 (72–95)	52.3 (41.7–61.0)	84 (43–95)
Individuals referred to cancer clinics due to family history	73 [‡] (68–78)		Not available	
Cases of breast or ovarian cancer unselected for family history (meta-analysis [§])	65 [‡] (51–75)		45 [‡] (33–54)	

* Where several studies were reviewed for a given category, only the results of the studies yielding the lowest and highest point estimates of penetrance are presented.

[†] The study families yielding the minimum penetrance estimate for *BRCA2* met selection criteria of ≥ 2 cases (or more restrictive criteria in some centres), whereas all other studies in this row selected families with ≥ 4 cases.

[‡] Only one study was identified by our search methodology.

[§] Meta-analysis combining data from 22 studies from heterogeneous and founder populations.

TABLE 3

Penetrance of *BRCA1/2* mutations for ovarian cancer estimated in different populations

TYPE OF POPULATION	PENETRANCE OF <i>BRCA1/2</i> MUTATIONS AT 70 YEARS, % (95% CI IF AVAILABLE)			
	<i>BRCA1</i>		<i>BRCA2</i>	
	MINIMUM VALUE*	MAXIMUM VALUE*	MINIMUM VALUE*	MAXIMUM VALUE*
Families ascertained for gene identification (multiple cases of cancer [†])	44 (28–56)	63	15.9 (8.8–22.5)	27 (0–47)
Individuals referred to cancer clinics due to family history	40.7 [‡] (35.7–45.6)		Not available	
Cases of breast or ovarian cancer unselected for family history (meta-analysis [§])	39 [‡] (22–51)		11 [‡] (4.1–18)	

* Where several studies were reviewed for a given category, only the results of the studies yielding the lowest and highest point estimates of penetrance are presented.

[†] The study families yielding the minimum penetrance estimate for *BRCA2* met selection criteria of ≥ 2 cases (or more restrictive criteria in some centres), whereas all other studies in this row selected families with ≥ 4 cases.

[‡] Only one study was identified by our search methodology.

[§] Meta-analysis combining data from 22 studies from heterogeneous and founder populations.

Given the complexity of the data on prevalence and penetrance of *BRCA* mutations, statistical modelling has been seen as a means of simplifying risk assessment and of identifying those families that are most likely to carry *BRCA* mutations. The earliest statistical models were designed to predict risk of breast cancer and did not integrate results of molecular testing. Subsequently, several models have been developed to estimate the probability of a *BRCA1/2* mutation explaining the familial aggregation of cancer. These models are either based on published data on population mutation prevalence, age-specific and cumulative penetrance and cancer incidence, or are derived from the analysis of samples of high-risk families fulfilling particular eligibility criteria and for whom molecular testing was performed. Some models are limited to *BRCA1* only, whereas others consider *BRCA1* and *BRCA2*. The range of risk factors integrated in these models is variable (AJ ancestry or male breast cancer may or may not be considered, for example), and such factors are not defined in a consistent way (for early onset of cancer, for instance). The complete family structure is not systematically considered. Most models, therefore, do not apply to all possible familial constellations of risk factors.

Some common predictors of *BRCA* mutation status have been identified through multivariate analysis. Among these, the presence of ovarian cancer and age at diagnosis are prominent. Although similar patterns emerge in the various models, specific results are still dependent upon the particular

study samples, the testing methods and the precise definitions of variables used.

A number of authors have compared the carrier probabilities generated by one or several models with *BRCA* mutation testing results. Others have compared the predictions of several models to each other. On the whole, these models are reported to have fairly high sensitivity¹⁵ and negative predictive value,¹⁶ but disappointing specificity¹⁷ and positive predictive value.¹⁸ The approaches used to compare the performance of these models are varied and sometimes questionable. In addition, most comparative studies have been performed on samples of exclusively high-risk families, so that the ability to discriminate between carrier and non-carrier families among borderline low- to moderate-risk families may not have been assessed accurately. More recent risk models strive to account for all facets of the familial aggregation of breast cancer and these may become important tools for risk assessment in the low- to moderate-risk range in the future. Efforts are also under way to develop more user-friendly tools for use in risk assessment in tertiary care and as referral guidelines for primary care.

The lack of proper validation and the numerous classification schemes of risk factors may contribute to the fact that none of these models has been unanimously adopted in clinical practice. Indeed, these statistical models are currently used as supplements to the genetic counsellor or clinical geneticist's own judgement of risk.

15. Sensitivity is the proportion of all persons with the target condition (be it a disease or a risk factor) for whom the test is positive.

16. Negative predictive value is the probability that individuals with negative results will not develop the disease.

17. Specificity is the proportion of all persons free of the target condition (be it a disease or a risk factor) for whom the test is negative.

18. Positive predictive value is the probability that people with positive test results will develop the disease.

Clinical guidelines have been produced by a variety of bodies on indications for performing molecular testing for *BRCA1/2* mutations or on risk classification schemes, with a view to referring families to the appropriate level of care. Most guidelines are based on expert opinion or are extrapolated from research study evidence. However, the links between the recommendations and the supporting evidence, i.e., the source and the specific levels of mutation penetrance and prevalence associated with familial and personal risk factors, are not stated.

Genetic testing is currently recommended for high-risk families only, and there is general concordance between the various guidelines as to the most important risk factors used to define high-risk families. The identified risk factors are consistent with findings from the literature on penetrance and prevalence and with the common results of the risk assessment statistical models discussed earlier. It should be noted that this concordance applies to broadly defined risk factors, such as early onset of breast cancer, male breast cancer, bilateral breast cancer, ovarian cancer, multiple affected family members and Ashkenazi Jewish ancestry. In contrast, there is little consensus as to the precise criteria that should guide testing within each of these broad risk factors, or the combination thereof. This is not a trivial issue, particularly if some risk factors are used in isolation. If, for instance, early age at diagnosis is used as a sufficient criterion for testing (without requirements with respect to number of cancer cases in relatives for instance), the choice of age cut-off greatly influences the number of tests being requested and the ability of laboratories and the

health-care system to assume these activities. A similar situation arises if male breast cancer or ovarian cancer is used without additional criteria related to age at onset or family history. If such guidelines were to be considered in Québec, the probability of detecting mutations under these conditions would have to be appropriately documented and the implications estimated, in terms of impact on services and health-care organization.

The most recent guidelines have placed more emphasis on criteria for referral to tertiary genetic services or for access to genetic counselling than on precise testing indications. Likewise, the 2003 statement from the American Society of Clinical Oncology has backed away from the use of a numerical threshold as a criterion to recommend *BRCA1/2* mutation testing, placing greater emphasis on the role of the evaluation made by health-care professionals experienced in cancer genetics in determining appropriateness of testing. Such a position may be more coherent with current practices and more realistic at the present time, given the limitations of available data and the lack of consensus around precise guidelines and statistical models. In terms of planning of clinical and laboratory services, flexible testing indications make it more difficult to predict volume of testing. Cost implications could be significant, if testing were to extend beyond the environment of specialized centres. In addition, flexible testing indications will defer standardization of practices and will thus have implications on future data collection, unless clear selection criteria are agreed upon for research and monitoring purposes.

The length of the *BRCA1* and *BRCA2* genes, the distribution of mutations throughout these genes, and the diversity of types of mutations found markedly complicate molecular analyses. No single technique is appropriate to detect all mutation types. The sequencing¹⁹ of all exons and splice site junctions²⁰ has traditionally been considered the gold standard technique to detect point mutations, small insertions and deletions²¹ in these parts of the genes. Sequencing is both costly and labour-intensive and is not an appropriate technique to detect large rearrangements, such as large deletions or insertions. The proportion of *BRCA1/2* mutations that cannot be detected by sequencing has been the object of research only in the past few years, and it has become clear that the proportion of large rearrangements, for *BRCA1* in particular, cannot be neglected.

Molecular tests are assessed for both their technical and clinical performance. Analytical validity refers to the technical performance of the test and reflects the comparison of test results with the genotype, or the DNA sequence. A literature review on analytical validity did not fall within the purview of this assessment. Clinical validity refers to the comparison of test results with the phenotype, i.e., the clinical expression of disease. Clinical validity is a function of the target population, depending both on the ethnic group and on the familial risk factors used to select study samples. Data were extracted from the literature to estimate clinical sensitivity²² of:

- 1) exon and splice site screening techniques (EX/SP screening, involving a variety of

methods) for heterogeneous (non-founder) populations, by examining the proportion of HBOC families carrying point mutations and small rearrangements in *BRCA1*, as opposed to large genomic rearrangements and non-coding region mutations;

- 2) testing for common mutations in different populations with founder effects (Ashkenazi Jewish, Polish, Dutch, Finnish, Hungarian and French Canadian), using the distribution of common and non-common *BRCA1/2* mutations; and

- 3) the protein truncation test (PTT).²³

Several methodological challenges were encountered in reviewing this literature. The approach we developed for deriving clinical sensitivity estimates accounts for the conceptual problems underlying these difficulties and the empirical constraints resulting from the quality and nature of available data. A wide variety of different molecular techniques are used both for the point mutation/small rearrangement search and for the detection of large rearrangements. Therefore, resulting data are implicitly dependent on the various levels of analytical sensitivity associated with these methods, and it is thus problematic to combine values across investigations. To account for the limited analytical sensitivity of most techniques used and the possibility of misclassification of families in which all genetic tests were negative (likely a mixture of false negative and true negative results), our clinical sensitivity estimates of EX/SP screening are expressed as a range of values. The minimum value places all the tested families in the denominator, including those who tested negative (with the assumption that they actually carry mutations); the maximum value excludes all negative families from the denominator (by assuming they are truly negative). At the time of our analysis, the literature on large *BRCA2* rearrangements was limited; our computations of

19. Sequencing is a molecular technique used to determine the exact nucleotide sequence of the DNA fragment.

20. Each gene contains several non-contiguous exons. Non-coding sequences (introns) are removed at the junction of exons and introns, also referred to as splice sites, to form the mature messenger RNA for translation into a protein.

21. A point mutation is a single nucleotide base pair change in DNA, whereas insertions and deletions refer to the presence and the loss of one or more consecutive base pairs, respectively.

22. Clinical sensitivity is one measure of clinical validity and refers to the proportion of individuals with the phenotype of the disease (or who will develop this phenotype) in whom the test will be positive.

23. This molecular method is based on the detection of a truncated (shortened) protein.

clinical sensitivity of EX/SP screening methods in heterogeneous populations therefore apply only to *BRCA1* mutations. Finally, the studies we identified involved testing only affected cases from HBOC families, which precludes evaluation of clinical specificity.²⁴

Among eligible studies, a single, small-scale study used sequencing for all families and the estimated clinical sensitivity varies from 65 to 76.5%. A greater range of estimates is obtained from the studies which used other EX/SP screening methods. If point mutation/small rearrangement and large rearrangement/non-coding region screening were systematically combined, a higher level of clinical sensitivity would be reached; however, exhaustive testing for large rearrangements and non-coding region mutations is not routine in the clinical setting. A number of laboratories have recently switched to combining the DHPLC technique with MLPA²⁵ analysis, but there were not enough data in the literature we reviewed to examine a joint clinical sensitivity for this approach.

Large variations in estimates of clinical sensitivity of techniques designed to detect point mutations and small insertions/deletions in exons and splice

site junctions are observed in the literature. These variations are in part related to founder effects for large deletions, described in the Dutch population, for example, in which large genomic rearrangements could contribute up to 38% of all clinically important *BRCA1* mutations in high-risk families; they are also the result of differences in study selection criteria and in methods for estimating clinical sensitivity. Underlying these discrepancies is the lack of an unequivocal definition of clinical validity and of the reference phenotype, as well as the progressive and technique-dependent accrual of knowledge. The result is an as yet incomplete portrait of the distribution of *BRCA1/2* mutations in most populations.

In populations with strong founder effects, such as the Ashkenazi Jewish, Icelandic and Polish populations, the testing protocol can be restricted to the search for the common founder mutations. Such testing strategies achieve comparable or even higher clinical sensitivity than the screening of all coding regions in heterogeneous populations. In Finland and Québec, in contrast, several common founder mutations have been identified, but their prevalence is lower and their distribution could vary by region.

24. Clinical specificity refers to the proportion of individuals who do not have the phenotype of the disease (and who will not develop this phenotype) and in whom the test will be negative.

25. DHPLC, or denaturing high performance liquid chromatography, is a technique recently used to detect point mutations and small rearrangements, whereas MLPA, or multiplex ligation-dependent probe amplification, is a recent technique detecting large rearrangements.

IMPACT OF TESTING ON RISK ASSESSMENT AND GENETIC COUNSELLING

The utility of testing is determined, in part, by the extent to which test results contribute to a more definite and precise risk assessment, both in terms of personal and familial risk. With respect to the establishment of an increased **familial** risk of breast and ovarian cancer, the identification of a *BRCA1/2* mutation provides confirmation of an increased risk, information which may be useful for families with an *a priori* moderate risk on the basis of the pedigree. In families with an *a priori* high risk, molecular testing may not substantially modify breast or ovarian cancer risk assessment, even if the test result is inconclusive (negative), because of the limited clinical sensitivity of most techniques. The detection (or not) of a *BRCA1/2* mutation may also affect the assessment of risk for other types of cancer (e.g., prostate cancer, male breast cancer).

The impact of testing on the **personal** risk assessment within moderate- to high-risk families is a different issue, and depends on whether a mutation has previously been identified in the family or not. If a mutation has been previously documented in a given family, a negative test result for that particular mutation brings the test-negative individual's risk down to that of the general population, assuming that the test's analytical validity is high and that only one mutation runs in the family. This finding has clear implications in terms of clinical management in the sense of a 'demedicalization' for the individual and her/his offspring. A positive test result, on the other hand, indicates a risk level clearly above that of the general population, but does not necessarily yield a precise estimate of the age-specific or cumulative risk of developing breast and/or ovarian cancer. Precise individual estimates would require detailed knowledge about the joint impact of genetic and environmental risk factors on disease probability, which is unlikely to become available. For current counselling purposes, a wide range is usually provided for the cumulative risk of disease expression. In some founder populations (e.g., Ashkenazi Jewish), risk figures that are specific

to particular mutations can be provided. In terms of consequences for family members, first-degree relatives can be informed of their 50% probability of having inherited the same mutation. This information may modify their risk perception and their interest in counselling and testing.

When a mutation has not been previously detected in the family, three outcomes are possible. If a mutation is detected in the index case²⁶ and is known to be deleterious, the interpretation of the test result is not particularly problematic, since it should be considered a true positive. In contrast, when a variant of unknown clinical significance (VUC) is detected, the *a priori* risk estimate remains applicable as long as the clinical significance of the sequence variation has not been clarified. This result should not be used to guide management decisions, and tests are usually not offered to other family members. To clarify whether the sequence variation has any impact on cancer risk, different types of investigations—both laboratory-based and epidemiological—may be required (e.g., analysis of proteins, association studies). For the genetic counsellor, this situation is particularly complex, and for the family, such an uninformative result is unlikely to relieve anxiety. The third possible outcome—when no DNA alteration is found—should be presented to the family as an 'inconclusive' result. Indeed, a *BRCA1/2* mutation may have been missed by the standard molecular techniques or the family may carry a mutation in another, yet undiscovered breast cancer susceptibility gene. The interpretation here is also complex because, depending on the family history, the post-test probability will either be reduced (but not to the general population level) or remain unchanged. In the latter case, decisions regarding clinical management would likely be based on the familial risk assessment.

The interpretation of a test result and its implications in terms of familial risk and personal management options are not straightforward,

26. An index case is an affected family member who first draws attention to a pedigree.

in view of the complexity and degree of uncertainty associated with some of these results. Interpretation of test results and estimation of post-test probabilities need to consider the pedigree information, the analytical and clinical validity of the technique used, and the penetrance and

nature of the detected mutation. Services need to be in place to support patients and families adequately. Qualified personnel and ample time have to be dedicated to providing this information and to allow an opportunity for questions and clarifications.

In the process of reviewing the literature for this report, important limitations in the evidence have been found. Major problems are the lack of a consensual definition of HBOC and the quality of the study designs and reporting of data, which are not up to epidemiological standards for molecular test evaluation studies. The variability in the study population selection criteria and in the testing protocols for molecular testing complicates the synthesis of the evidence. This variability is particularly striking in the literature on prevalence, penetrance and clinical validity. Current knowledge in areas such as the distribution of *BRCA1/2* mutations is dependent on the evolution of molecular techniques and testing criteria. Both prevalence and penetrance have been studied more thoroughly in high-risk families and in some founder populations than in families at moderate or low risk. Residual uncertainties and gaps in current knowledge have implications regarding decision making for individuals and families, for health-care providers and for policy makers.

Among the conditions put forward by the American Society of Clinical Oncology for molecular testing in cancer genetics in general, the evidence was reviewed with respect to the assessment of prior (pre-test) risk based on family history and on the informativeness of test results for the post-test updating of the risk assessment. As far as current practices are concerned, the majority of families considered eligible for testing in cancer genetics clinics (typically families with two or three affected individuals) are not found to carry a *BRCA1/2* mutation. Such a result is considered inconclusive and the residual risk of cancer remains higher than that of the general population. Providing precise post-test probabilities to these families is, however, difficult because good data on clinical negative predictive value are lacking. Another inconclusive test result which represents a challenging task for geneticists and genetic counsellors and does not substantially alleviate a family's anxiety, is the discovery of a variant of

unknown clinical significance. This situation is relatively frequent, possibly almost as frequent as a positive test finding, but may be resolved over time as new knowledge about these variants accrues. In practice, for the very high risk families, the pre-test (prior) risk will not be substantially modified by an inconclusive test result.

Testing primarily benefits families in which a *BRCA1/2* mutation has been discovered. For unaffected relatives who undergo testing and are found not to carry the mutation present in the family, breast cancer risk drops from a high prior probability to a post-test risk comparable to that in the general population. Unaffected relatives in whom a mutation is identified, on the other hand, have a substantially higher cancer risk than that of the general population. In addition, individuals with breast or ovarian cancer in whom a *BRCA1/2* mutation is identified are at increased risk of developing a second cancer. For families in which a *BRCA1/2* mutation is identified, both positive and negative test results have implications for clinical management, either in the sense of a 'demedicalization' or of increased requirements for surveillance, prevention or prophylactic measures. A review of the effectiveness of these interventions did not fall within the purview of this report.

Consequently, a balanced view of benefits and risks, and formal recommendations with respect to the use of *BRCA1/2* mutation testing, cannot be presented at this time. It is, however, already apparent that the balance of benefits and risks will be heavily dependent on the prior risk assessment and that the knowledge base to derive decisions is stronger for high-risk families than for populations at lower risk. In the subsequent AETMIS report, the forthcoming evidence from other systematic reviews on issues such as the analytical validity of molecular tests, the psychosocial consequences of testing, and the effectiveness of available interventions will be integrated with our further analysis of the economic and organizational issues surrounding cancer genetic services.

APPENDIX A

LITERATURE SEARCH

Searches of the following databases were completed to the end of June 2004: PubMed, Cochrane Library, Dialog® OneSearch® on MEDLINE®, CANCERLIT®, EMBASE®, Biosis Previews®, and PASCAL. In addition, PubMed, CANCERLIT®, and EMBASE® were searched from July to end of December, 2004. A preliminary investigation revealed extensive literature, particularly on prevalence and penetrance, subsequent to the cloning of *BRCA1* and *BRCA2* in 1994 and 1995, respectively. The following strategies were therefore used:

- 1) The literature search for primary research articles was restricted to January 1999 onwards. An additional search for review articles published from 2001 to 2002 was conducted, and the reference lists of these articles were examined to identify key primary research articles published before 1999.
- 2) For the risk assessment chapter, review articles published from 2001 and 2002 were used to describe models developed before 1999. Contact was also made with clinical practice experts in cancer genetics from Québec, Ontario, and British Columbia to confirm that the models and tools most often used in clinical care were included in this chapter.
- 3) Clinical practice guidelines on test indications were examined from 1996 onwards, as the clinical use of *BRCA* genetic testing was first discussed in guidelines in that year. Guidelines listed in the Inherit BRCA database [INHERIT BRCA, 2001] were examined.
- 4) For the clinical validity chapter, besides studies on mutation prevalence, articles on the performance of molecular tests for *BRCA1/2* were also examined to identify studies on large genomic rearrangements and non-coding mutations.

Grey literature was identified by searching the INAHTA (International Network of Agencies for Health Technology Assessment) websites, other health agency websites, clinical trial registries, clinical practice guideline databases, websites of relevant societies and associations (for conference abstracts), and other specialized databases.

STUDY SELECTION CRITERIA

The selection criteria used for each topic are listed below.

Prevalence and penetrance

The selection criteria for material on prevalence and penetrance were the following:

- 1) Primary research study published since 1999.
- 2) Sample size ($n \geq 100$) for samples selected for family history.
 - Families could be a mixture of breast cancer only, ovarian cancer only, or breast-ovarian families, or the sample could be entirely made up of one of these groups.
 - No sample size cut-off was used for Canadian studies of this type.
- 3) Sample size ($n \geq 500$) for samples not selected for family history.
 - These were usually persons affected with cancer, and selection for age at onset/diagnosis was allowed.
 - No sample size cut-off was used for Canadian studies or for studies of this type from Iceland (due to the small number of studies available for the Icelandic population).

- ‘Key’ articles (i.e., frequently cited primary research) published before 1999 were identified using 33 review articles from January 2001 to June 2002 and using reference lists from primary research articles which met the selection criteria. For key articles which studied persons unselected for family history, the sample size cut-off was lowered to at least 100 persons.
 - For samples not selected on the basis of family history nor age at onset/diagnosis, the sample size cut-off was lowered to at least 100 persons if the study sample was from USA, United Kingdom or France (the two last countries being major founding regions for the Canadian and American populations).
- 4) For key articles on Ashkenazi Jewish persons, testing for all 3 frequent *BRCA1/2* founder mutations was necessary (i.e., *BRCA1* 185delAG, *BRCA1* 5382insC, *BRCA2* 6174delT).
 - 5) Abstracts were excluded, due to the large number of peer-reviewed primary research articles in this area, except for those presented at a recent large genetics conference (American Society of Human Genetics, Toronto, October 2004).

Review articles and additional primary research articles that were suggested by a genetics expert were used in the discussion of variability of penetrance and in the section on other cancers. These issues were not the primary focus of the systematic review on prevalence and penetrance.

Risk assessment

No sample size restrictions were used as criteria for this topic. To be included in the data extraction, a primary research study (published since 1999) had to develop and/or test predictive risk models (these models were developed using *BRCA1/2* mutation testing or estimates of *BRCA1/2* prevalence/penetrance and cancer incidence). Simulation studies and segregation analyses used to develop explanatory models and purely methodological papers were excluded.

Testing indications

No sample size restrictions were used as criteria for material on testing indications. Guidelines were selected that specifically mentioned indications for *BRCA* genetic testing or referral to family cancer clinics, clinical geneticists, genetic counsellors, etc.; some of these also discussed clinical management (management details were not summarized). Recommendations for referral to different levels of specialized care (within which a decision to test for mutations may or may not be made) were included since these also gave an idea of the risk levels in use in clinical practice.

Clinical validity

No sample size restrictions were used as criteria for clinical validity material. A search was carried out for primary research on the prevalence of *BRCA1/2* mutations or on *BRCA* mutation testing methods that potentially contained information on the distribution of susceptibility mutations. Due to the relative scarcity of material, abstracts were not excluded in the search for this topic.

REFERENCES

- ABC Study Group. Prevalence and penetrance of *BRCA1* and *BRCA2* mutations in a population-based series of breast cancer cases—ABC Study Group. *Br J Cancer* 2000;83(10):1301–8.
- Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, et al. The founder mutations 185delAG and 5382insC in *BRCA1* and 6174delT in *BRCA2* appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. *Am J Hum Genet* 1997;60(3):505–14.
- Abkevich V, Zharkikh A, Deffenbaugh A, Chen Y, Shattuck D, Skolnick M, et al. Analysis of missense variation in human *BRCA1* in the context of interspecific sequence variation. *J Med Genet* 2004;41(7):492–507.
- Allweis TM, Sagi M, Peretz T. Genetic counseling for women with breast cancer: The importance of evaluating the spouse. *Clin Genet* 2004;66(6):573–4.
- American College of Medical Genetics (ACMG). Position statement on gene patents and accessibility of gene testing. *Genet Med* 1999a;1(5):237. Available at: <http://www.acmg.net/resources/policies/pol-015.asp>.
- American College of Medical Genetics Foundation (ACMG). Genetic susceptibility to breast and ovarian cancer: Assessment, counseling and testing guidelines. 1999b. Available at: <http://www.health.state.ny.us/nysdoh/cancer/obcancer/contents.htm>.
- American College of Medical Genetics (ACMG). Statement on population screening for *BRCA1* mutation in Ashkenazi Jewish women. 1996. Available at: <http://www.acmg.net/resources/policies/pol-002.asp>.
- American College of Obstetricians and Gynecologists (ACOG). Committee on genetics. ACOG committee opinion. Breast-ovarian cancer screening. Number 239, August 2000. *Int J Gynaecol Obstet* 2001;75(3):339–40.
- American Society of Clinical Oncology (ASCO). American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. *J Clin Oncol* 2003;21(12):2397–406.
- American Society of Clinical Oncology (ASCO). Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. *J Clin Oncol* 1996;14(5):1730–40.
- Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. *J Med Genet* 2003;40(11):807–14.
- Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, et al. Comparison of DNA- and RNA-based methods for detection of truncating *BRCA1* mutations. *Hum Mutat* 2002;20(1):65–73.
- Ang P and Garber J. Genetic susceptibility for breast cancer-risk assessment and counseling. *Semin Oncol* 2001;28(4):419–33.
- Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of *BRCA1* mutations in a population-based case series of breast and ovarian cancer. *Eur J Cancer* 2000;36(10):1200–8.

- Antoniou AC, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Breast and ovarian cancer risks to carriers of the *BRCA1* 5382insC and 185delAG and *BRCA2* 6174delT mutations: A combined analysis of 22 population based studies. *J Med Genet* 2005;42(7):602–3.
- Antoniou AC, Pharoah PD, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. *Br J Cancer* 2004;91(8):1580–90.
- Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with *BRCA1* or *BRCA2* mutations detected in case series unselected for family history: A combined analysis of 22 studies. *Am J Hum Genet* 2003;72(5):1117–30.
- Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, et al. A comprehensive model for familial breast cancer incorporating *BRCA1*, *BRCA2* and other genes. *Br J Cancer* 2002;86(1):76–83.
- Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. *Genet Epidemiol* 2000;18(2):173–90.
- Apicella C, Andrews L, Hodgson SV, Fisher SA, Lewis CM, Solomon E, et al. Log odds of carrying an Ancestral Mutation in *BRCA1* or *BRCA2* for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA). *Breast Cancer Res* 2003;5(6):R206–16.
- Aretini P, D’Andrea E, Pasini B, Viel A, Costantini RM, Cortesi L, et al. Different expressivity of *BRCA1* and *BRCA2*: Analysis of 179 Italian pedigrees with identified mutation. *Breast Cancer Res Treat* 2003;81(1):71–9.
- Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. *N Engl J Med* 2000;342(8):564–71.
- Arver B, Borg A, Lindblom A. First *BRCA1* and *BRCA2* gene testing implemented in the health care system of Stockholm. *Genet Test* 2001;5(1):1–8.
- Auranen A, Spurdle AB, Chen X, Lipscombe J, Purdie DM, Hopper JL, et al. *BRCA2* Arg372His polymorphism and epithelial ovarian cancer risk. *Int J Cancer* 2003;103(3):427–30.
- Backe J, Hofferbert S, Skawran B, Dork T, Stuhmann M, Karstens JH, et al. Frequency of *BRCA1* mutation 5382insC in German breast cancer patients. *Gynecol Oncol* 1999;72(3):402–6.
- Bahar AY, Taylor PJ, Andrews L, Proos A, Burnett L, Tucker K, et al. The frequency of founder mutations in the *BRCA1*, *BRCA2*, and *APC* genes in Australian Ashkenazi Jews: Implications for the generality of U.S. population data. *Cancer* 2001;92(2):440–5.
- Bansal A, Critchfield GC, Frank TS, Reid JE, Thomas A, Deffenbaugh AM, Neuhausen SL. The predictive value of *BRCA1* and *BRCA2* mutation testing. *Genet Test* 2000;4(1):45–8.
- Barcnas CH, Zong J, Hosain GM, Strong LC, Mills GB, Amos CI. Evaluation of a *BRCA* carrier probability model with a random component for extended families. *Am J Hum Genet* 2003;73(Suppl):617.
- Barnes-Kedar IM and Plon SE. Counseling the at risk patient in the *BRCA1* and *BRCA2* Era. *Obstet Gynecol Clin North Am* 2002;29(2):341–66, vii.

- Becher H and Chang-Claude J. Estimating the sensitivity of a genetic test using gene-carrier probability estimates and its application in genetic counselling. *J Cancer Epidemiol Prev* 2002;7(1):13–9.
- Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, et al. Frequency of germline and somatic *BRCA1* mutations in ovarian cancer. *Clin Cancer Res* 1998;4(10):2433–7.
- Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, et al. BRCAPRO validation, sensitivity of genetic testing of *BRCA1/BRCA2*, and prevalence of other breast cancer susceptibility genes. *J Clin Oncol* 2002;20(11):2701–12.
- Blamey RW, Baidam A, Bates T, Bishop H, Bristol J, Cunliffe W, et al. The British Association of Surgical Oncology Guidelines for surgeons in the management of symptomatic breast disease in the UK (1998 revision)—BASO Breast Specialty Group. *Eur J Surg Oncol* 1998;24(6):464–76.
- Blancquaert I and Caron L. Fragile X syndrome: the role of molecular diagnosis and screening in an integrated approach to services. Montreal: Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS); 2002.
- Blesa JR and Hernandez-Yago J. Adaptation of conformation-sensitive gel electrophoresis to an ALFexpress DNA sequencer to screen *BRCA1* mutations. *Biotechniques* 2000;28(5):1019–25.
- Borg A. Molecular and pathological characterization of inherited breast cancer. *Semin Cancer Biol* 2001;11(5):375–85.
- BRCA1* Exon 13 Duplication Screening Group. The exon 13 duplication in the *BRCA1* gene is a founder mutation present in geographically diverse populations. *Am J Hum Genet* 2000;67(1):207–12.
- Breast Cancer Linkage Consortium (BCLC). Cancer risks in *BRCA2* mutation carriers. *J Natl Cancer Inst* 1999;91(15):1310–6.
- Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for *BRCA1* mutation carriers identified in a risk evaluation program. *J Natl Cancer Inst* 2002;94(18):1365–72.
- Bryant H. Breast Cancer in Canadian Women. *BMC Women's Health* 2004;4(Suppl 1):S12.
- Bunyan DJ, Eccles DM, Sillibourne J, Wilkins E, Thomas NS, Shea-Simonds J, et al. Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. *Br J Cancer* 2004;91(6):1155–9.
- Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. *BRCA1* and *BRCA2*—Cancer Genetics Studies Consortium. *JAMA* 1997;277(12):997–1003.
- Cancer Genetics Service in Wales (CGSW). Referral guidelines for individuals with a family history of cancer. 2003. Available at: http://phgu.org.uk/info_database/diseases/cancer/cancer_wales.html.
- Cancer Genetics Sub-Group of the Scottish Cancer Group (SCG). Cancer genetics services in Scotland: Guidance to support the implementation of genetics services for breast, ovarian and colorectal cancer predisposition. 2001. Available at: http://www.show.scot.nhs.uk/sehd/mels/HDL2001_24GuideFull.pdf.

- Cancer Research Campaign (CRC). Familial breast cancer and ovarian cancer: A management guide for primary care. 2001. Available at: <http://www.dphpc.ox.ac.uk/crcpcerg/resources/genpack.htm>.
- CancerBACUP Medical Advisory Committee. Familial risk and genetics in common cancers: Bowel, breast and ovary. 2001. Available at: <http://www.cancerbacup.org.uk/reports/familial-mac.htm>.
- Carter RF. *BRCA1*, *BRCA2* and breast cancer: A concise clinical review. *Clin Invest Med* 2001;24(3):147–57.
- Casey MJ and Bewtra C. Peritoneal carcinoma in women with genetic susceptibility: Implications for Jewish populations. *Fam Cancer* 2004;3(3-4):265–81.
- Casilli F, Di Rocco ZC, Gad S, Tournier I, Stoppa-Lyonnet D, Frebourg T, Tosi M. Rapid detection of novel *BRCA1* rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. *Hum Mutat* 2002;20(3):218–26.
- Chang-Claude J. Inherited genetic susceptibility to breast cancer. In: Miller A, Bartsch H, Boffetta P, Dragsted L, Vainio H, eds. *Biomarkers in cancer chemoprevention*. Lyon, France: IARC (IARC Sci Publ No. 154); 2001 : 177–90.
- Chang-Claude J, Becher H, Caligo M, Eccles D, Evans G, Haites N, et al. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer. *Dis Markers* 1999;15(1-3):53–65.
- Chappuis PO and Foulkes WD. Risk assessment and genetic testing. *Cancer Treat Res* 2002;107:29–59.
- Chappuis PO, Hamel N, Paradis AJ, Deschenes J, Robidoux A, Potvin C, et al. Prevalence of founder *BRCA1* and *BRCA2* mutations in unselected French Canadian women with breast cancer. *Clin Genet* 2001;59(6):418–23.
- Chatterjee N, Hartge P, Wacholder S. Adjustment for competing risk in kin-cohort estimation. *Genet Epidemiol* 2003;25(4):303–13.
- CHEK2* Breast Cancer Case-Control Consortium. *CHEK2**1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. *Am J Hum Genet* 2004;74(6):1175–82.
- Cipollini G, Tommasi S, Paradiso A, Aretini P, Bonatti F, Brunetti I, et al. Genetic alterations in hereditary breast cancer. *Ann Oncol* 2004;15(Suppl 1):I7–I13.
- Claes K, Poppe B, Coene I, Paepe AD, Messiaen L. *BRCA1* and *BRCA2* germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. *Br J Cancer* 2004;90(6):1244–51.
- Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: Implications for risk prediction. *Cancer* 1994;73(3):643–51.
- Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. *Am J Hum Genet* 1991;48(2):232–42.

- Clinical Molecular Genetics Society (CMGS). Gene patents and clinical molecular genetic testing in the UK: Threats, weaknesses, opportunities and strengths. 1999. Available at: <http://www.cmgs.org/patents.htm>.
- Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC). Comprehensive analysis of 989 patients with breast or ovarian cancer provides *BRCA1* and *BRCA2* mutation profiles and frequencies for the German population. *Int J Cancer* 2002;97(4):472–80.
- Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC). Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. *Lancet* 2001;358(9291):1389–99.
- Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, et al. *BRCA1* mutations in women attending clinics that evaluate the risk of breast cancer. *N Engl J Med* 1997;336(20):1409–15.
- Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, et al. *BRCA2* germline mutations in male breast cancer cases and breast cancer families. *Nat Genet* 1996;13(1):123–5.
- Cui J, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, et al. After *BRCA1* and *BRCA2*—What next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. *Am J Hum Genet* 2001;68(2):420–31.
- Culver J, Hull J, Levy-Lahad E, Daly M, Burke W. *BRCA1* and *BRCA2* hereditary breast/ovarian cancer. 2000. Available at: <http://www.geneclinics.org>.
- Cummings S and Olopade O. Predisposition testing for inherited breast cancer. *Oncology (Huntingt)* 1998;12(8):1227–42.
- Cuzick J. Epidemiology of breast cancer: Selected highlights. *Breast* 2003;12(6):405–11.
- Daly M, Angelos P, Bryant E, Buys S, Eng C, Engstrom PF, et al. NCCN practice guidelines: Genetics/familial high-risk cancer screening. *Oncology* 1999;13(11A):161–83.
- De Bock GH, Vliet Vlieland TP, Hageman GC, Oosterwijk JC, Springer MP, Kievit J. The assessment of genetic risk of breast cancer: A set of GP guidelines. *Fam Pract* 1999;16(1):71–7.
- De la Hoya M, Diez O, Perez-Segura P, Godino J, Fernandez JM, Sanz J, et al. Pre-test prediction models of *BRCA1* or *BRCA2* mutation in breast/ovarian families attending familial cancer clinics. *J Med Genet* 2003;40(7):503–10.
- De la Hoya M, Osorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, et al. Association between *BRCA1* and *BRCA2* mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. *Int J Cancer* 2002;97(4):466–71.
- Deffenbaugh AM, Frank TS, Hoffman M, Cannon-Albright L, Neuhausen SL. Characterization of common *BRCA1* and *BRCA2* variants. *Genet Test* 2002;6(2):119–21.

- Devilee P. *BRCA1* and *BRCA2* testing: Weighing the demand against the benefits. *Am J Hum Genet* 1999;64(4):943–8.
- Diez O, Osorio A, Duran M, Martinez-Ferrandis JI, de la Hoya M, Salazar R, et al. Analysis of *BRCA1* and *BRCA2* genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects. *Hum Mutat* 2003;22(4):301–12.
- Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MR, et al. Familial risks, early-onset breast cancer, and *BRCA1* and *BRCA2* germline mutations. *J Natl Cancer Inst* 2003;95(6):448–57.
- Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL. Application of breast cancer risk prediction models in clinical practice. *J Clin Oncol* 2003;21(4):593–601.
- Dorum A, Hovig E, Trope C, Inganas M, Moller P. Three per cent of Norwegian ovarian cancers are caused by *BRCA1* 1675delA or 1135insA. *Eur J Cancer* 1999a;35(5):779–81.
- Dorum A, Heimdal K, Hovig E, Inganas M, Moller P. Penetrances of *BRCA1* 1675delA and 1135insA with respect to breast cancer and ovarian cancer. *Am J Hum Genet* 1999b;65(3):671–9.
- Dorum A, Kristensen GB, Abeler VM, Trope CG, Moller P. Early detection of familial ovarian cancer. *Eur J Cancer* 1996;32A(10):1645–51.
- Durocher F, Antoniou A, Smith P, Dumont M, Laframboise R, Chiquette J, et al. Penetrance estimates of deleterious of *BRCA1* and *BRCA2* mutations in high-risk French Canadian families. Abstracts: The American Society of Human Genetics, 54th Annual Meeting. Bethesda MD: ASHG; 2004 : A564.
- Durocher F, Tonin P, Shattuck-Eidens D, Skolnick M, Narod SA, Simard J. Mutation analysis of the *BRCA1* gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. *J Med Genet* 1996;33(10):814–9.
- Easton DF, Hopper JL, Thomas DC, Antoniou A, Pharoah PD, Whittemore AS, Haile RW. Breast cancer risks for *BRCA1/2* carriers. *Science* 2004;306(5705):2187–91.
- Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in *BRCA1*-mutation carriers. Breast Cancer Linkage Consortium. *Am J Hum Genet* 1995;56(1):265–71.
- Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. The Breast Cancer Linkage Consortium. *Am J Hum Genet* 1993;52(4):678–701.
- Eccles DM, Evans DG, Mackay J. Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG). *J Med Genet* 2000;37(3):203–9.
- Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the *BRCA2* gene. *Am J Hum Genet* 2003;72(1):1–12.

- Edwards SM, Kote-Jarai Z, Hamoudi R, Eeles RA. An improved high throughput heteroduplex mutation detection system for screening *BRCA2* mutations- uorescent mutation detection (F-MD). *Hum Mutat* 2001;17(3):220–32.
- Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP, et al. [Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004)]—French National Ad Hoc Committee. *Bull Cancer* 2004;91(3):219–37 (article in French whose original title is: *Identification et prise en charge des prédispositions héréditaires aux cancers du sein et de l'ovaire (mise à jour 2004)*).
- Eisinger F, Alby N, Bremond A, Dauplat J, Espie M, Janiaud P, et al. Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee. *Ann Oncol* 1998;9(9):939–50.
- Elit L. Familial ovarian cancer. *Can Fam Physician* 2001;47:778–84.
- Eng C, Brody LC, Wagner TM, Devilee P, Vijg J, Szabo C, et al. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in *BRCA1*. *J Med Genet* 2001;38(12):824–33.
- Euhus DM, Leitch AM, Huth JF, Peters GN. Limitations of the Gail model in the specialized breast cancer risk assessment clinic. *Breast J* 2002a;8(1):23–7.
- Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, et al. Pretest prediction of *BRCA1* or *BRCA2* mutation by risk counselors and the computer model BRCAPRO. *J Natl Cancer Inst* 2002b;94(11):844–51.
- Evans DG, Neuhausen SL, Bulman M, Young K, Gokhale D, Laloo F. Haplotype and cancer risk analysis of two common mutations, *BRCA1* 4184del4 and *BRCA2* 2157delG, in high risk northwest England breast/ovarian families. *J Med Genet* 2004a;41(2):e21.
- Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, et al. A new scoring system for the chances of identifying a *BRCA1/2* mutation outperforms existing models including BRCAPRO. *J Med Genet* 2004b;41(6):474–80.
- Evans DG, Bulman M, Young K, Gokhale D, Laloo F. Sensitivity of *BRCA1/2* mutation testing in 466 breast/ovarian cancer families. *J Med Genet* 2003;40(9):e107.
- Farrell C. Appendix III: Risk measurement and assessment: Breast and ovarian cancer. In: *Genetic Susceptibility to Breast and Ovarian Cancer: Assessment, Counseling, and Testing Guidelines*. New York: New York State Department of Health and the American College of Medical Genetics; 1999. Available at: <http://www.health.state.ny.us/nysdoh/cancer/obcancer/contents.htm>
- Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am A, Beck D, et al. Patients with double primary tumors in the breast and ovary—Clinical characteristics and *BRCA1-2* mutations status. *Gynecol Oncol* 2000;79(1):74–8.
- FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, et al. Germ-line *BRCA1* mutations in Jewish and non-Jewish women with early-onset breast cancer. *N Engl J Med* 1996;334(3):143–9.

- Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, et al. Frequency and carrier risk associated with common *BRCA1* and *BRCA2* mutations in Ashkenazi Jewish breast cancer patients. *Am J Hum Genet* 1998;63(1):45–51.
- Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the *BRCA1* and *BRCA2* genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet* 1998;62(3):676–89.
- Ford D, Easton DF, Peto J. Estimates of the gene frequency of *BRCA1* and its contribution to breast and ovarian cancer incidence. *Am J Hum Genet* 1995;57(6):1457–62.
- Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in *BRCA1*-mutation carriers. Breast Cancer Linkage Consortium. *Lancet* 1994;343(8899):692–5.
- Foulkes WD, Brunet JS, Wong N, Goff J, Chappuis PO. Change in the penetrance of founder *BRCA1/2* mutations? A retrospective cohort study. *J Med Genet* 2002;39(6):407–9.
- Foulkes WD, Brunet JS, Warner E, Goodwin PJ, Meschino W, Narod SA, et al. The importance of a family history of breast cancer in predicting the presence of a *BRCA* mutation. *Am J Hum Genet* 1999;65(6):1776–9.
- Frank TS and Critchfield GC. Identifying and managing hereditary risk of breast and ovarian cancer. *Clin Perinatol* 2001;28(2):395–406.
- Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in *BRCA1* and *BRCA2*: Analysis of 10,000 individuals. *J Clin Oncol* 2002;20(6):1480–90.
- Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, et al. Sequence analysis of *BRCA1* and *BRCA2*: Correlation of mutations with family history and ovarian cancer risk. *J Clin Oncol* 1998;16(7):2417–25.
- Fries MH, Holt C, Carpenter I, Carter CL, Daniels J, Flanagan J, et al. Diagnostic criteria for testing for *BRCA1* and *BRCA2*: The experience of the Department of Defense Familial Breast/Ovarian Cancer Research Project. *Mil Med* 2002a;167(2):99–103.
- Fries MH, Holt C, Carpenter I, Carter CL, Daniels J, Flanagan J, et al. Guidelines for evaluation of patients at risk for inherited breast and ovarian cancer: Recommendations of the Department of Defense Familial Breast/Ovarian Cancer Research Project. *Mil Med* 2002b;167(2):93–8.
- Gad S, Klinger M, Caux-Moncoutier V, Pages-Berhouet S, Gauthier-Villars M, Coupier I, et al. Bar code screening on combed DNA for large rearrangements of the *BRCA1* and *BRCA2* genes in French breast cancer families. *J Med Genet* 2002;39(11):817–21.
- Gad S, Aurias A, Puget N, Mairal A, Schurra C, Montagna M, et al. Color bar coding the *BRCA1* gene on combed DNA: A useful strategy for detecting large gene rearrangements. *Genes Chromosomes Cancer* 2001;31(1):75–84.
- Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst* 1989;81(24):1879–86.

- Gayther SA, Russell P, Harrington P, Antoniou AC, Easton DF, Ponder BA. The contribution of germline *BRCA1* and *BRCA2* mutations to familial ovarian cancer: No evidence for other ovarian cancer-susceptibility genes. *Am J Hum Genet* 1999;65(4):1021–9.
- Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the *BRCA2* gene. *Nat Genet* 1997;15(1):103–5.
- Ghadirian P, Lubinski J, Lynch H, Neuhausen SL, Weber B, Isaacs C, et al. Smoking and the risk of breast cancer among carriers of *BRCA* mutations. *Int J Cancer* 2004;110(3):413–6.
- Gilpin CA, Carson N, Hunter AG. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. *Clin Genet* 2000;58(4):299–308.
- Gladstone C. Screening for ovarian cancer. In: Canadian Task Force on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa, ON : Health Canada; 1994 : 870–81.
- Goldgar D, Easton D, Deffenbaugh A, Monteiro A, Tavtigian S, Couch F, Breast Cancer Information Core (BIC) Steering Committee. Integrated evaluation of DNA sequence variants of unknown clinical significance: Application to *BRCA1* and *BRCA2*. *Am J Hum Genet* 2004;75(4):535–44.
- Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, et al. A high proportion of founder *BRCA1* mutations in Polish breast cancer families. *Int J Cancer* 2004a;110(5):683–6.
- Gorski B, Menkiszak J, Gronwald J, Lubinski J, Narod S. A protein truncating *BRCA1* allele with a low penetrance of breast cancer. *J Med Genet* 2004b;41(12):e130.
- Haites N and Gregory H. Overview of the clinical genetics of breast cancer. In: Morrison P, Hodgson S, Haites N, eds. Familial breast and ovarian cancer. Genetics, screening and management. Cambridge University Press; 2002 : 6–21.
- Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. *Science* 1990;250(4988):1684–9.
- Hamel N, Kotar K, Foulkes WD. Founder mutations in *BRCA1/2* are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. *BMC Med Genet* 2003;4:7.
- Hartge P, Struwing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common *BRCA1* and *BRCA2* mutations among Ashkenazi Jews. *Am J Hum Genet* 1999; 64(4):963–70.
- Hartmann C, John AL, Klaes R, Hofmann W, Bielen R, Koehler R, et al. Large *BRCA1* gene deletions are found in 3% of German high-risk breast cancer families. *Hum Mutat* 2004;24(6):534.
- Health Technology Advisory Committee (HTAC). Genetic testing for susceptibility to breast cancer. Minnesota Department of Health, 1998. Available at: <http://www.health.state.mn.us/htac/gt.htm>.
- Heimdal K, Maehle L, Apold J, Pedersen JC, Moller P. The Norwegian founder mutations in *BRCA1*: High penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. *Eur J Cancer* 2003;39(15):2205–13.

- Hemminki K and Granstrom C. Familial invasive and borderline ovarian tumors by proband status, age and histology. *Int J Cancer* 2003;105(5):701–5.
- Hendrickson B, Deffenbaugh AM, Gaglio CA, Judkins T, Chen S, Ward BE, Scholl T. Prevalence results for five recurrent *BRCA1* rearrangement mutations in 7570 analyses. *Am J Hum Genet* 2003;73(Suppl):253.
- Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R, et al. Population attributes affecting the prevalence of *BRCA* mutation carriers in epithelial ovarian cancer cases in Israel. *Gynecol Oncol* 2003;89(3):494–8.
- Hodgson SV, Morrison PJ, Irving M. Breast cancer genetics: Unsolved questions and open perspectives in an expanding clinical practice. *Am J Med Genet C Semin Med Genet* 2004;129(1):56–64.
- Hodgson SV, Heap E, Cameron J, Ellis D, Mathew CG, Eeles RA, et al. Risk factors for detecting germline *BRCA1* and *BRCA2* founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. *J Med Genet* 1999;36(5):369–73.
- Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, et al. Large genomic deletions and duplications in the *BRCA1* gene identified by a novel quantitative method. *Cancer Res* 2003;63(7):1449–53.
- Hogervorst FB, Cornelis RS, Bout M, van Vliet M, Oosterwijk JC, Olmer R, et al. Rapid detection of *BRCA1* mutations by the protein truncation test. *Nat Genet* 1995;10(2):208–12.
- Holtzman NA and Watson MS (eds). Promoting safe and effective genetic testing in the United States: Final report of the Task Force on Genetic Testing. National Human Genome Research Institute (NHGRI), Task Force on Genetic Testing; 1997. Available at: <http://www.genome.gov/10001733> (accessed on March 15, 2005).
- Hopper JL. Genetic epidemiology of female breast cancer. *Semin Cancer Biol* 2001;11(5):367–74.
- Hopper JL and Jenkins MA. Modeling the probability that Ashkenazi Jewish women carry a founder mutation in *BRCA1* or *BRCA2*. *Am J Hum Genet* 1999;65(6):1771–6.
- Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in *BRCA1* and *BRCA2*. Australian Breast Cancer Family Study. *Cancer Epidemiol Biomarkers Prev* 1999;8(9):741–7.
- Hosking L, Au K, Sanséau P. Mutation detection in cancer susceptibility. In: Foulkes W, Hodgson S, eds. *Inherited susceptibility to cancer. Clinical, predictive and ethical perspectives*. Cambridge University Press; 1998 : 134–49.
- Hoskins KF, Stopfer JE, Calzone KA, Merajver SD, Rebbeck TR, Garber JE, Weber BL. Assessment and counseling for women with a family history of breast cancer: A guide for clinicians. *JAMA* 1995;273(7):577–85.
- Houlston RS and Peto J. The search for low-penetrance cancer susceptibility alleles. *Oncogene* 2004;23(38):6471–6.

- Huusko P, Paakkonen K, Launonen V, Poyhonen M, Blanco G, Kauppila A, et al. Evidence of founder mutations in Finnish *BRCA1* and *BRCA2* families. *Am J Hum Genet* 1998;62(6):1544–8.
- Iau PT, Macmillan RD, Blamey RW. Germ line mutations associated with breast cancer susceptibility. *Eur J Cancer* 2001;37(3):300–21.
- Interdisciplinary Health Research International Team on Breast Cancer susceptibility (INHERIT BRCA). INHERIT BRCA guidelines database. 2001. Available at: http://www.inheritbrcas.info/CancerGen/en/GenBiblio_q.cfm (accessed on March 21, 2005).
- International Agency for Research on Cancer (IARC). Current research topics. Genetic Epidemiology Research Unit. Lyon, France : IARC; 2004. Available at: <http://www.iarc.fr>.
- Janezic SA, Ziogas A, Krumroy LM, Krasner M, Plummer SJ, Cohen P, et al. Germline *BRCA1* alterations in a population-based series of ovarian cancer cases. *Hum Mol Genet* 1999;8(5):889–97.
- Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, et al. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. *Cancer Res* 1996;56(16):3663–5.
- Jonker MA, Jacobi CE, Hoogendoorn WE, Nagelkerke NJ, de Bock GH, van Houwelingen JC. Modeling familial clustered breast cancer using published data. *Cancer Epidemiol Biomarkers Prev* 2003;12(12):1479–85.
- Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD. Influence of *BRCA1* mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. *Cancer* 1997;80(3):435–41.
- King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in *BRCA1* and *BRCA2*. *Science* 2003;302(5645):643–6.
- Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, et al. Frequency of *BRCA1* and *BRCA2* mutations in unselected Ashkenazi Jewish patients with colorectal cancer. *J Natl Cancer Inst* 2004;96(1):68–70.
- Klimberg VS, Galandiuk S, Singletary ES, Cohen A, Sener S, Talamonti MS, et al. Society of Surgical Oncology: Statement on genetic testing for cancer susceptibility. Committee on Issues and Governmental Affairs of the Society of Surgical Oncology. *Ann Surg Oncol* 1999;6(5):507–9.
- Kmet L, Lee RC, Cook LS, Lorenzetti D, Godlovith G, Einsiedel E. Systematic review of the social, ethical and legal dimensions of genetic cancer risk assessment technologies. Calgary, AB: Alberta Heritage Foundation for Medical Research (AHFMR); 2004.
- Knight JA, Sutherland HJ, Glendon G, Boyd NF, Andrulis IL. Characteristics associated with participation at various stages at the Ontario site of the cooperative family registry for breast cancer studies. *Ann Epidemiol* 2002;12(1):27–33.
- Koenig BA, Greely HT, McConnell LM, Silverberg HL, Raf n TA. Genetic testing for *BRCA1* and *BRCA2*: Recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group. *J Womens Health* 1998;7(5):531–45.

- Kutner SE. Breast cancer genetics and managed care. The Kaiser Permanente experience. *Cancer* 1999;86(11 Suppl):2570–4.
- Ladopoulos A, Kroupis C, Konstantopoulou I, Ioannidou-Mouzaka L, Schoeld AC, Pantazidis A, et al. Germ line *BRCA1* & *BRCA2* mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. *Cancer Lett* 2002;185(1):61–70.
- Lahti-Domenici J, Rapakko K, Paakkonen K, Allinen M, Nevanlinna H, Kujala M, et al. Exclusion of large deletions and other rearrangements in *BRCA1* and *BRCA2* in Finnish breast and ovarian cancer families. *Cancer Genet Cytogenet* 2001;129(2):120–3.
- Langston AA and Ostrander EA. Hereditary ovarian cancer. *Curr Opin Obstet Gynecol* 1997;9(1):3–7.
- Ligtenberg MJ, Hogervorst FB, Willems HW, Arts PJ, Brink G, Hageman S, et al. Characteristics of small breast and/or ovarian cancer families with germline mutations in *BRCA1* and *BRCA2*. *Br J Cancer* 1999;79(9-10):1475–8.
- Loman N, Bladstrom A, Johannsson O, Borg A, Olsson H. Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known *BRCA1* and *BRCA2* mutation status. *Breast Cancer Res* 2003;5(6):R175–86.
- Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. *Cochrane Database Syst Rev* 2004;(4):CD002748.
- Lucassen A, Watson E, Harcourt J, Rose P, O’Grady J. Guidelines for referral to a regional genetics service: GPs respond by referring more appropriate cases—Oxford Regional Genetics Service (ORGS). *Fam Pract* 2001;18(2):135–40.
- Lynch HT and Krush AJ. Carcinoma of the breast and ovary in three families. *Surg Gynecol Obstet* 1971;133(4):644–8.
- Lynch HT, Shaw TG, Lynch JF. Inherited predisposition to cancer: A historical overview. *Am J Med Genet C Semin Med Genet* 2004;129(1):5–22.
- Lynch HT, Krush AJ, Lipp M. The delay problem in cancer. *Med Times* 1972;100(11):76–87.
- Malander S, Ridderheim M, Masback A, Loman N, Kristoffersson U, Olsson H, et al. One in 10 ovarian cancer patients carry germ line *BRCA1* or *BRCA2* mutations: Results of a prospective study in Southern Sweden. *Eur J Cancer* 2004;40(3):422–8.
- Malone KE, Daling JR, Neal C, Suter NM, O’Brien C, Cushing-Haugen K, et al. Frequency of *BRCA1*/*BRCA2* mutations in a population-based sample of young breast carcinoma cases. *Cancer* 2000;88(6):1393–402.
- Marroni F, Aretini P, D’Andrea E, Caligo MA, Cortesi L, Viel A, et al. Evaluation of widely used models for predicting *BRCA1* and *BRCA2* mutations. *J Med Genet* 2004;41(4):278–85.
- Martin AM, Blackwood MA, Antin-Ozerkis D, Shih HA, Calzone K, Colligon TA, et al. Germline mutations in *BRCA1* and *BRCA2* in breast-ovarian families from a breast cancer risk evaluation clinic. *J Clin Oncol* 2001;19(8):2247–53.

- Meindl A, Hofmann W, Scherneck S, Horn D, Paepke S, Grumann M, et al. Comprehensive analysis of 989 patients with breast or ovarian cancer provides *BRCA1* and *BRCA2* mutation profiles and frequencies for the German population—German Consortium for Hereditary Breast and Ovarian Cancer. *Int J Cancer* 2002;97(4):472–80.
- Menczer J, Chetrit A, Barda G, Lubin F, Fishler Y, Altaras M, et al. Frequency of *BRCA* mutations in primary peritoneal carcinoma in Israeli Jewish women. *Gynecol Oncol* 2003;88(1):58–61.
- Menkiszak J, Gronwald J, Gorski B, Jakubowska A, Huzarski T, Byrski T, et al. Hereditary ovarian cancer in Poland. *Int J Cancer* 2003;106(6):942–5.
- Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene *BRCA1*. *Science* 1994;266(5182):66–71.
- Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of *BRCA1* and *BRCA2* mutations. *Cancer Epidemiol Biomarkers Prev* 2005;14(2):350–6.
- Mirkovic N, Marti-Renom M, Weber B, Sali A, Monteiro A. Structure-based assessment of missense mutations in human *BRCA1*: Implications for breast and ovarian cancer predisposition. *Cancer Res* 2004;64(11):3790–7.
- Møller P, Evans G, Haites N, Vasen H, Reis MM, Anderson E, et al. Guidelines for follow-up of women at high risk for inherited breast cancer: Consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. *Dis Markers* 1999;15(1-3):207–11.
- Montagna M, Dalla Palma M, Menin C, Agata S, De Nicolo A, Chieco-Bianchi L, D’Andrea E. Genomic rearrangements account for more than one-third of the *BRCA1* mutations in northern Italian breast/ovarian cancer families. *Hum Mol Genet* 2003;12(9):1055–61.
- Montagna M, Agata S, De Nicolo A, Menin C, Sordi G, Chieco-Bianchi L, D’Andrea E. Identification of *BRCA1* and *BRCA2* carriers by allele-specific gene expression (AGE) analysis. *Int J Cancer* 2002;98(5):732–6.
- Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, et al. *BRCA1* and *BRCA2* mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. *Am J Hum Genet* 2000;66(4):1259–72.
- Myriad Genetic Laboratories. Technical note. 2004. Available at: http://www.myriadtests.com/provider/doc/tech_specs_brac.pdf.
- Narod SA and Boyd J. Current understanding of the epidemiology and clinical implications of *BRCA1* and *BRCA2* mutations for ovarian cancer. *Curr Opin Obstet Gynecol* 2002;14(1):19–26.
- Narod SA and Foulkes WD. *BRCA1* and *BRCA2*: 1994 and beyond. *Nat Rev Cancer* 2004;4(9):665–76.
- Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, et al. Oral contraceptives and the risk of breast cancer in *BRCA1* and *BRCA2* mutation carriers. *J Natl Cancer Inst* 2002;94(23):1773–9.
- Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. *Am J Hum Genet* 1995;56(1):254–64.

- Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: What we know and what we need. *Nat Med* 2001;7(5):552–6.
- National Action Plan on Breast Cancer (NAPBC) and National Cancer Institute. Genetic testing for breast cancer risk. 1997. Available at: <http://www.nci.nih.gov/cancerinfo/genetic-testing-breast>.
- National Breast Cancer Coalition (NBCC). Presymptomatic genetic testing for heritable breast cancer risk. Washington, DC: 1996.
- National Comprehensive Cancer Network (NCCN). Genetic/familial high-risk assessment: Breast and ovarian. Clinical Practice Guidelines in Oncology version 1.2004. NCCN; 2005. Available at: http://www.southalabama.edu/usahealthsystem/surgery/pdf/genetics_screening.pdf (accessed on January 31, 2005).
- National Health and Medical Research Council (NHMRC). Familial aspects of cancer: A guide to clinical practice (clinical practice guidelines). 1999. Available at: http://www7.health.gov.au/nhmrc/publications/_les/cp67.pdf.
- National Health and Medical Research Council (NHMRC) and National Breast Cancer Coalition (NBCC). Advice about familial aspects of breast cancer and ovarian cancer: A guide for health professionals. 2000. Available at: http://www.nbcc.org.au/bestpractice/resources/BOG_BreastOvarianGuideSimpl.pdf (accessed on February 15, 2005).
- National Institute for Clinical Excellence (NICE). Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. Clinical Guideline 14. NICE; 2004. Available at: <http://www.nice.org.uk/CG014NICEguideline>.
- National Screening Committee (NSC). National Screening Committee report on workshop: Screening for late onset genetic disorders: Breast and ovarian cancer. 2001. Available at: <http://rms.nelh.nhs.uk/screening/viewResource.asp?searchText=late+onset+genetic+disorders&searchZone=%2Fscreening%2FsearchResponse.asp&dg=107&uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D61150>.
- National Society of Genetic Counselors (NSGC). Code of Ethics. August 1991. Available at: http://www.nsgc.org/newsroom/code_of_ethics.asp.
- Nedelcu R, Liede A, Aube J, Finch A, Kwan E, Jack E, et al. *BRCA* mutations in Italian breast/ovarian cancer families. *Eur J Hum Genet* 2002;10(2):150–2.
- Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to *BRCA1* in a population-based series of American women. *JAMA* 1998;279(12):915–21.
- Newman LA, Kuerer HM, Hunt KK, Vlastos G, Ames FC, Ross MI, Singletary SE. Educational review: Role of the surgeon in hereditary breast cancer. *Ann Surg Oncol* 2001;8(4):368–78.
- Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB. *BRCA1* and *BRCA2* founder mutations and the risk of colorectal cancer. *J Natl Cancer Inst* 2004;96(1):15–21.

- Nkondjock A and Ghadirian P. Epidemiology of breast cancer among *BRCA* mutation carriers: An overview. *Cancer Lett* 2004;205(1):1–8.
- Noorani H and McGahan L. Predictive genetic testing for breast and prostate cancer. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment; 2000.
- Nordling M, Karlsson P, Wahlstrom J, Engwall Y, Wallgren A, Martinsson T. A large deletion disrupts the exon 3 transcription activation domain of the *BRCA2* gene in a breast/ovarian cancer family. *Cancer Res* 1998;58(7):1372–5.
- Olopade OI and Cummings S. Breast and ovarian cancer. Part 2, counseling patients about risk. *Consultant* 2000;40(11):1930–7.
- Olschwang S, Bonaiti C, Feingold J, Frebourg T, Grandjouan S, Lasset C, et al. [HNPCC syndrome (hereditary non polyposis colon cancer): Identification and management]. *Rev Med Interne* 2005;26(2):109–18 (article in French whose original title is: *Identification et prise en charge du syndrome HPNCC (hereditary non polyposis colon cancer) : prédisposition héréditaire aux cancers du côlon, du rectum et de l'utérus*).
- Oncology Nursing Society (ONS USA). Cancer predisposition genetic testing and risk assessment counseling. *Oncol Nurs Forum* 2000;27 (9):1349.
- Ontario Predictive Cancer Genetics Steering Committee (OPCGSC). Criteria for genetic testing for *BRCA1* and *BRCA2* in the province of Ontario. 2001. Available at: <http://www.oma.org/pcomm/omr/nov/01genetics.htm>.
- Oros KK, Ghadirian P, Greenwood CM, Perret C, Shen Z, Paredes Y, et al. Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 *BRCA1* and *BRCA2* mutations. *Int J Cancer* 2004;112(3):411–9.
- Ozcelik H, Knight JA, Glendon G, Yazici H, Carson N, Ainsworth PJ, et al. Individual and family characteristics associated with protein truncating *BRCA1* and *BRCA2* mutations in an Ontario population based series from the Cooperative Family Registry for Breast Cancer Studies. *J Med Genet* 2003;40(8):e91.
- Papelard H, de Bock GH, van Eijk R, Vliet Vlieland TP, Cornelisse CJ, Devilee P, Tollenaar RA. Prevalence of *BRCA1* in a hospital-based population of Dutch breast cancer patients. *Br J Cancer* 2000;83(6):719–24.
- Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes *BRCA1* and *BRCA2*. *Am J Hum Genet* 1998;62(1):145–58.
- Peelen T, de Leeuw W, van Lent K, Morreau H, van Eijk R, van Vliet M, et al. Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to *BRCA1*, fails to support a role for *BRCA1* in colorectal tumorigenesis. *Int J Cancer* 2000a;88(5):778–82.
- Peelen T, van Vliet M, Bosch A, Bignell G, Vasen HF, Klijn JG, et al. Screening for *BRCA2* mutations in 81 Dutch breast-ovarian cancer families. *Br J Cancer* 2000b;82(1):151–6.

- Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AM, et al. A high proportion of novel mutations in *BRCA1* with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. *Am J Hum Genet* 1997;60(5):1041–9.
- Peelen T, Cornelis RS, van Vliet M, Petrij-Bosch A, Cleton-Jansen AM, Meijers-Heijboer H, et al. The majority of 22 Dutch high-risk breast cancer families are due to either *BRCA1* or *BRCA2*. *Eur J Hum Genet* 1996;4(4):225–30.
- Peshkin BN, DeMarco TA, Brogan BM, Lerman C, Isaacs C. *BRCA1/2* testing: Complex themes in result interpretation. *J Clin Oncol* 2001;19(9):2555–65.
- Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, et al. Prevalence of *BRCA1* and *BRCA2* gene mutations in patients with early-onset breast cancer. *J Natl Cancer Inst* 1999;91(11):943–9.
- Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, et al. *BRCA1* genomic deletions are major founder mutations in Dutch breast cancer patients. *Nat Genet* 1997;17(3):341–5.
- Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. *Nat Rev Cancer* 2004;4(11):850–60.
- Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. *Nat Genet* 2002;31(1):33–6.
- Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: A systematic review and meta-analysis. *Int J Cancer* 1997;71(5):800–9.
- Phelan CM, Kwan E, Jack E, Li S, Morgan C, Aube J, et al. A low frequency of non-founder *BRCA1* mutations in Ashkenazi Jewish breast-ovarian cancer families. *Hum Mutat* 2002;20(5):352–7.
- Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, et al. Mutation analysis of the *BRCA2* gene in 49 site-specific breast cancer families. *Nat Genet* 1996;13(1):120–2.
- Pinsky LE, Culver JB, Hull J, Levy-Lahad E, Daly M, Burke W. Why should primary care physicians know about breast cancer genetics? *West J Med* 2001;175(3):168–73.
- Public Health Genetics Unit (PHGU). Report of consensus meeting on the management of women with a family history of breast cancer. R&D Office of the Anglia & Oxford NHS Executive and the Unit for Public Health Genetics, Cambridge, 1998. Available at: http://www.phgu.org.uk/info_database/public_documents/breastcaconsen.html.
- Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Pages S, Lynch HT, Lenoir GM, Mazoyer S. Screening for germ-line rearrangements and regulatory mutations in *BRCA1* led to the identification of four new deletions. *Cancer Res* 1999a;59(2):455–61.
- Puget N, Sinilnikova OM, Stoppa-Lyonnet D, Audoynaud C, Pages S, Lynch HT, et al. An Alu-mediated 6-kb duplication in the *BRCA1* gene: A new founder mutation? *Am J Hum Genet* 1999b;64(1):300–2.
- Puget N, Torchard D, Serova-Sinilnikova OM, Lynch HT, Feunteun J, Lenoir GM, Mazoyer S. A 1-kb Alu-mediated germ-line deletion removing *BRCA1* exon 17. *Cancer Res* 1997;57(5):828–31.

- Rafnar T, Benediktsdottir KR, Eldon BJ, Gestsson T, Saemundsson H, Olafsson K, et al. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: A population-based study. *Eur J Cancer* 2004;40(18):2788–93.
- Ramus SJ, Kote-Jarai Z, Friedman LS, van der Looij M, Gayther SA, Csokay B, et al. Analysis of *BRCA1* and *BRCA2* mutations in Hungarian families with breast or breast-ovarian cancer. *Am J Hum Genet* 1997;60(5):1242–6.
- Rebbeck TR. Inherited predisposition and breast cancer: Modifiers of BRCA1/2-associated breast cancer risk. *Environ Mol Mutagen* 2002;39(2-3):228–34.
- Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline *BRCA1* and *BRCA2* mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet* 2001;68 (3):700–10.
- Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in *BRCA1* and *BRCA2*. *Nat Genet* 1996;14(2):185–7.
- Robson M, Levin D, Federici M, Satagopan J, Bogolminy F, Heerdt A, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with *BRCA* gene founder mutations. *J Natl Cancer Inst* 1999;91(24):2112–7.
- Robson ME, Boyd J, Borgen PI, Cody HS. Hereditary breast cancer. *Curr Probl Surg* 2001;38(6):387–480.
- Rostagno P, Gioanni J, Garino E, Vallino P, Namer M, Frenay M. A mutation analysis of the *BRCA1* gene in 140 families from southeast France with a history of breast and/or ovarian cancer. *J Hum Genet* 2003;48(7):362–6.
- Royal Australian College of General Practitioners (RACGP). Current best advice about familial aspects of breast cancer: A guide for general practitioners. 1997. Available at: <http://www.nbcc.org.au/pages/info/resource/nbccpubs/advice.htm>.
- Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, Boyd J. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: Relationship to family history and implications for genetic testing. *Am J Obstet Gynecol* 1998;178(4):670–7.
- Sarantaus L, Vahteristo P, Bloom E, Tamminen A, Unkila-Kallio L, Butzow R, Nevanlinna H. *BRCA1* and *BRCA2* mutations among 233 unselected Finnish ovarian carcinoma patients. *Eur J Hum Genet* 2001;9(6):424–30.
- Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K. Ovarian cancer risk in Ashkenazi Jewish carriers of *BRCA1* and *BRCA2* mutations. *Clin Cancer Res* 2002;8(12):3776–81.
- Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of *BRCA1* and *BRCA2* mutations. *Cancer Epidemiol Biomarkers Prev* 2001;10(5):467–73.

- Sauven P, Bailsam A, Eeles R, Evans G, Gilbert F, Gui G, et al. Guidelines for the management of women at increased familial risk of breast cancer— Association of Breast Surgery Family History Guidelines Panel (ABS). *Eur J Cancer* 2004;40(5):653–65.
- Schneider KA. *Counseling about cancer: Strategies for genetic counseling*. 2nd ed. New York : Wiley-Liss; 2002.
- Schubert EL, Mefford HC, Dann JL, Argonza RH, Hull J, King MC. *BRCA1* and *BRCA2* mutations in Ashkenazi Jewish families with breast and ovarian cancer. *Genet Test* 1997;1(1):41–6.
- Scottish Intercollegiate Guidelines Network (SIGN). Epithelial ovarian cancer. National Clinical Guideline no. 75. SIGN; 2003. Available at: <http://www.sign.ac.uk/guidelines/fulltext/75/index.html> (accessed on January 13, 2005).
- Scottish Intercollegiate Guidelines Network (SIGN). Breast cancer in women. National Clinical Guideline no. 29. 1998. Available at: <http://www.sign.ac.uk/guidelines/fulltext/29/index.html>.
- Sellner LN and Taylor GR. MLPA and MAPH: New techniques for detection of gene deletions. *Hum Mutat* 2004;23(5):413–9.
- Serova O, Montagna M, Torchard D, Narod SA, Tonin P, Sylla B, et al. A high incidence of *BRCA1* mutations in 20 breast-ovarian cancer families. *Am J Hum Genet* 1996;58(1):42–51.
- Serova-Sinilnikova OM, Boutrand L, Stoppa-Lyonnet D, Bressac-de-Paillerets B, Dubois V, Lasset C, et al. *BRCA2* mutations in hereditary breast and ovarian cancer in France. *Am J Hum Genet* 1997;60(5):1236–9.
- Shannon KM, Lubratovich ML, Finkelstein DM, Smith BL, Powell SN, Seiden MV. Model-based predictions of *BRCA1/2* mutation status in breast carcinoma patients treated at an academic medical center. *Cancer* 2002;94 (2):305–13.
- Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, et al. *BRCA1* sequence analysis in women at high risk for susceptibility mutations: Risk factor analysis and implications for genetic testing. *JAMA* 1997;278(15):1242–50.
- Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, et al. A collaborative survey of 80 mutations in the *BRCA1* breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. *JAMA* 1995;273(7):535–41.
- Shih HA, Couch FJ, Nathanson KL, Blackwood MA, Rebbeck TR, Armstrong KA, et al. *BRCA1* and *BRCA2* mutation frequency in women evaluated in a breast cancer risk evaluation clinic. *J Clin Oncol* 2002;20(4):994–9.
- Shiri-Sverdlov R, Gershoni-Baruch R, Ichezekel-Hirsch G, Gotlieb WH, Bruchim Bar-Sade R, Chetrit A, et al. The Tyr978X *BRCA1* mutation in non-Ashkenazi Jews: Occurrence in high-risk families, general population and unselected ovarian cancer patients. *Community Genet* 2001;4(1):50–5.
- Simard J, Dumont M, Moisan AM, Durocher F, Laframboise R, Plante M, et al. Molecular epidemiology of *BRCA1* and *BRCA2* mutations in French Canadian breast/ovarian families. Abstracts: The American Society of Human Genetics, 54th Annual Meeting. Bethesda MD: ASHG; 2004 : A480.

- Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, et al. Common origins of *BRCA1* mutations in Canadian breast and ovarian cancer families. *Nat Genet* 1994;8(4):392–8.
- Singleton SE. Rating the risk factors for breast cancer. *Ann Surg* 2003;237(4):474–82.
- Spurdle A, Healey S, Bekessy A, Marsh A, Tavtigian S, Goldgar D, et al.. Classification of unclassified variants in *BRCA1* and *BRCA2*. Abstracts: The American Society of Human Genetics, 54th Annual Meeting. Bethesda, MD: ASHG; 2004 : A561.
- Spurdle AB, Hopper JL, Chen X, Dite GS, Cui J, McCredie MR, et al. The *BRCA2* 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. *Cancer Epidemiol Biomarkers Prev* 2002;11(4):413–6.
- Srivastava A, McKinnon W, Wood ME. Risk of breast and ovarian cancer in women with strong family histories. *Oncology (Huntingt)* 2001;15(7):889–902; discussion 902, 905–7, 911–13.
- Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, Pages S, Ithier G, Ligot L, et al. *BRCA1* sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. *Am J Hum Genet* 1997;60(5):1021–30.
- Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, et al. Contribution of *BRCA1* mutations to ovarian cancer. *N Engl J Med* 1997;336(16):1125–30.
- Struwing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of *BRCA1* and *BRCA2* among Ashkenazi Jews. *N Engl J Med* 1997;336(20):1401–8.
- Stuppia L, Di Fulvio P, Aceto G, Pintor S, Veschi S, Gatta V, et al. *BRCA1* and *BRCA2* mutations in breast/ovarian cancer patients from central Italy. *Hum Mutat* 2003;22(2):178–9.
- Sutcliffe S, Pharoah PD, Easton DF, Ponder BA. Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer. *Int J Cancer* 2000;87(1):110–7.
- Suter NM, Ray RM, Hu YW, Lin MG, Porter P, Gao DL, et al. *BRCA1* and *BRCA2* mutations in women from Shanghai China. *Cancer Epidemiol Biomarkers Prev* 2004;13(2):181–9.
- Swensen J, Hoffman M, Skolnick MH, Neuhausen SL. Identification of a 14 kb deletion involving the promoter region of *BRCA1* in a breast cancer family. *Hum Mol Genet* 1997;6(9):1513–7.
- Swedish Council on Technology Assessment in Health Care (SBU). Presymptomatic diagnosis of hereditary breast cancer. Stockholm, Sweden : SBU; 2000. Available at: <http://www.sbu.se/Filer/Content0/publikationer/3/Hereditary.pdf>.
- Swisher E. Hereditary cancers in obstetrics and gynecology. *Clin Obstet Gynecol* 2001;44(3):450–63.
- Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantausta L, et al. Population-based study of *BRCA1* and *BRCA2* mutations in 1035 unselected Finnish breast cancer patients. *J Natl Cancer Inst* 2000;92(18):1529–31.
- Takahashi H, Chiu HC, Bandera CA, Behbakht K, Liu PC, Couch FJ, et al. Mutations of the *BRCA2* gene in ovarian carcinomas. *Cancer Res* 1996;56(12):2738–41.

- Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, Weber BL, et al. Mutation analysis of the *BRCA1* gene in ovarian cancers. *Cancer Res* 1995;55(14):2998–3002.
- Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete *BRCA2* gene and mutations in chromosome 13q-linked kindreds. *Nat Genet* 1996;12(3):333–7.
- Taylor MR. Genetic testing for inherited breast and ovarian cancer syndromes: Important concepts for the primary care physician. *Postgrad Med J* 2001;77(903):11–5.
- Thompson D and Easton DF. Cancer Incidence in *BRCA1* mutation carriers. *J Natl Cancer Inst* 2002;94(18):1358–65.
- Thompson D, Easton D, Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in *BRCA2* mutation carriers. *Am J Hum Genet* 2001;68(2):410–9.
- Thompson M, McInnes R, Willard H. Thompson and Thompson Genetics in medicine. 5th ed. Philadelphia, PA : Saunders; 1991.
- Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, et al. Population-based study of risk of breast cancer in carriers of *BRCA2* mutation. *Lancet* 1998;352(9137):1337–9.
- Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, et al. Study of a single *BRCA2* mutation with high carrier frequency in a small population. *Am J Hum Genet* 1997;60(5):1079–84.
- Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, et al. A single *BRCA2* mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. *Nat Genet* 1996;13(1):117–9.
- Tonin P, Weber B, Of t K, Couch F, Rebbeck TR, Neuhausen S, et al. Frequency of recurrent *BRCA1* and *BRCA2* mutations in Ashkenazi Jewish breast cancer families. *Nat Med* 1996;2(11):1179–83.
- Tonin PN, Perret C, Lambert JA, Paradis AJ, Kantemiroff T, Benoit MH, et al. Founder *BRCA1* and *BRCA2* mutations in early-onset French Canadian breast cancer cases unselected for family history. *Int J Cancer* 2001;95(3):189–93.
- Tonin PN, Mes-Masson AM, Narod SA, Ghadirian P, Provencher D. Founder *BRCA1* and *BRCA2* mutations in French Canadian ovarian cancer cases unselected for family history. *Clin Genet* 1999;55(5):318–24.
- Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, et al. Founder *BRCA1* and *BRCA2* mutations in French Canadian breast and ovarian cancer families. *Am J Hum Genet* 1998;63(5):1341–51.
- Tournier I, Paillerets BB, Sobol H, Stoppa-Lyonnet D, Lidereau R, Barrois M, et al. Significant contribution of germline *BRCA2* rearrangements in male breast cancer families. *Cancer Res* 2004;64(22):8143–7.

- Tryggvadottir L, Olafsdottir EJ, Gudlaugsdottir S, Thorlacius S, Jonasson JG, Tulinius H, Eyfjord JE. *BRCA2* mutation carriers, reproductive factors and breast cancer risk. *Breast Cancer Res* 2003;5(5):R121–8.
- Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. *Nat Rev Cancer* 2004;4(10):814–9.
- Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. *Stat Med* 2004;23(7):1111–30.
- Unger MA and Weber BL. Recent advances in breast cancer biology. *Curr Opin Oncol* 2000;12(6):521–5.
- Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies *BRCA1* mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. *Am J Hum Genet* 2000;67(4):841–850.
- US Preventive Services Task Force (USPSTF), Agency for Healthcare Research and Quality (AHRQ). Genetic risk assessment and *BRCA* mutation testing for breast and ovarian cancer susceptibility. Evidence Synthesis No. 37, 2005.
- Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H. A probability model for predicting *BRCA1* and *BRCA2* mutations in breast and breast-ovarian cancer families. *Br J Cancer* 2001;84(5):704–8.
- Van Asperen CJ, Jonker MA, Jacobi CE, van Diemen-Homan JE, Bakker E, Breuning MH, et al. Risk estimation for healthy women from breast cancer families: New insights and new strategies. *Cancer Epidemiol Biomarkers Prev* 2004;13(1):87–93.
- Van Asperen CJ, de Bock GH, van der Horst F, de Koning HJ, Rutgers EJ. [Screening for breast cancer on basis of individual risk assessment for women ineligible for the national population screening program]— Kwaliteitsinstituut voor de Gezondheidszorg CBO. *Ned Tijdschr Geneesk* 2001;145(3):120–5 article in Dutch whose original title is: Screening op mammacarcinoom buiten het landelijke bevolkingsonderzoek, op grond van individuele risico-inschatting).
- Van Der Looij M, Szabo C, Besznyak I, Liszka G, Csokay B, Pulay T, et al. Prevalence of founder *BRCA1* and *BRCA2* mutations among breast and ovarian cancer patients in Hungary. *Int J Cancer* 2000;86(5):737–40.
- Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, et al. Low proportion of *BRCA1* and *BRCA2* mutations in Finnish breast cancer families: Evidence for additional susceptibility genes. *Hum Mol Genet* 1997a;6(13):2309–15.
- Vehmanen P, Friedman LS, Eerola H, Sarantaus L, Pyrhonen S, Ponder BA, et al. A low proportion of *BRCA2* mutations in Finnish breast cancer families. *Am J Hum Genet* 1997b;60(5):1050–8.

- Velasco Sampedro E, Esteban Cardenosa E, Infante Sanz M, Duran Dominguez M, Lastra Aras E, Garcia Giron C, Miner Pino C. [Molecular study of the *BRCA1* and *BRCA2* genes in 153 breast cancer families from Castilla and Leon (Spain): New nine unclassified variants identified] *Med Clin (Barc)* 2002;119(12):441–5 (article in Spanish whose original title is: *Estudio molecular de los genes BRCA1 y BRCA2 en 153 familias con càncer de mama de Castilla y León (España): identificación de nueve variantes de efecto desconocido no descritas*).
- Verhoog LC, van den Ouweland AM, Berns E, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, et al. Large regional differences in the frequency of distinct *BRCA1/BRCA2* mutations in 517 Dutch breast and/or ovarian cancer families. *Eur J Cancer* 2001;37(16):2082–90.
- Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA. Breast cancer risks for *BRCA1/2* carriers. *Science* 2004;306(5705):2187–91.
- Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, et al. Prevalence and penetrance of *BRCA1* and *BRCA2* gene mutations in unselected Ashkenazi Jewish women with breast cancer. *J Natl Cancer Inst* 1999;91(14):1241–7.
- Weitzel JN. Genetic cancer risk assessment: Putting it all together. *Cancer* 1999;86(11 Suppl):2483–92.
- Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RC, Marks J, Berchuck A. Polymorphisms in *BRCA1* and *BRCA2* and risk of epithelial ovarian cancer. *Clin Cancer Res* 2003;9(12):4396–403.
- Whittemore AS, Gong G, John EM, McGuire V, Li FP, Ostrow KL, et al. Prevalence of *BRCA1* mutation carriers among U.S. non-Hispanic Whites. *Cancer Epidemiol Biomarkers Prev* 2004;13(12):2078–83.
- Wolpert N, Warner E, Seminsky MF, Futreal A, Narod SA. Prevalence of *BRCA1* and *BRCA2* mutations in male breast cancer patients in Canada. *Clin Breast Cancer* 2000;1(1):57–65.
- Wooster R and Weber BL. Breast and ovarian cancer. *N Engl J Med* 2003;348(23):2339–47.
- Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene *BRCA2*. *Nature* 1995;378(6559):789–92.
- Xiao W and Oefner PJ. Denaturing high-performance liquid chromatography: A review. *Hum Mutat* 2001;17(6):439–74.

**Agence d'évaluation
des technologies
et des modes
d'intervention en santé**

Québec

